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DNA’s programmable nature and ability to self-assemble provides a powerful tool 
for the construction of complex nanostructures. The initial goal of the field was to use 
DNA to construct a continuous 3D DNA periodic lattice or crystal. The ultimate aim of the 
lattice structure would be to act as scaffold for the strategic placement of guest molecules 
such as macromolecules for structure determination using X-ray. Since that initial vision, 
the incorporation of guest molecules in DNA nanostructures has expanded to other 
applications such as cellular imaging, light-harvesting and drug delivery. However, there 
are several limitations to utilizing DNA crystals for these types of applications. They 
require relatively high cation concentrations to crystallize and often have low thermal 
stability.  Additionally, crystals generally take on only one shape, or morphology, which 
can limit their uses in applications.  
Our laboratory studies a 13-mer DNA oligonucleotide that self-assembles into 
crystals upon the addition of magnesium. I demonstrated that by treating these DNA 
crystals with a chemical crosslinker and depositing polydopamine on the crystal surface, 
 
 
we increased the overall durability of the crystals. Additionally, we modulated the 
morphology of the crystal without changing the underlying framework by designing crystal 
habit modifiers based on the known crystal structure and were able to predictably control 
the morphology of the overall crystal. This enhanced durability has allowed us to begin 
testing new applications for DNA crystals. I have explored the incorporation of 
doxorubicin into the stabilized DNA crystals as a potential form of a new drug delivery 
device. Together, this work significantly advanced several key areas necessary to diversify 
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Chapter 1: Introduction  
 
DNA has become one of the most widely used biomolecules for programmed self-
assembly at the nanoscale1. The features that make DNA an ideal template for genetic storage 
make it suitable as a building material for the construction of nanostructures. First, the B-form 
DNA duplex has consistent structural features with a diameter of 2 nm, a helical pitch of 3.4 nm, 
and a persistence length of 50 nm or ~150 bp2. Second, the hydrogen bonds that contribute to the 
formation and maintenance of the DNA duplex in vivo allow DNA to self-assemble in vitro. 
Lastly, the predictable G-C and A-T base pair that encodes the hereditary information is a 
valuable feature in designing and predicting DNA nanostructures. The ability for self-
complementary DNAs to base pair into predictable structures have allowed the creation of a wide 
variety of nanoscale DNA objects in two and three dimensions3–17.  
The field of DNA nanotechnology proliferated due to the favorable self-complementary 
features of DNA, and the low cost and facile synthesis of DNA oligomers18. As a result, there 
was a surge in the quantity and diversity of DNA nanostructures generated. The structures 
ranged from discrete 2D and 3D dimensional structures to continuous, periodic DNA arrays. The 
general classes of DNA nanostructures include: 2D DNA tile arrays assembled from crossovers 
and sticky ends5 , discrete 3D structures utilizes sticky ends for branching3, DNA origami 
assembled by folding a kilobase size strand using small staple stands7 , DNA bricks self-
assembled using 32 nucleotide lego-like blocks 16, DNA hydrogels19, and lastly DNA 
crystals17,20.  The diverse DNA nanostructures generated have enabled potential expansion of 
different types of applications. DNA nanostructures are being developed as photonic networks 
for energy transfer 21, biosensors22, templates for lipid bilayer formation23, drug delivery24,25, 
biocatalysts26 and molecular sieves27. DNA is no longer associated purely with the field of 
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biology as a genetic material, but has entered into the field of material science as a nano-building 
block.  
The earliest goal of the DNA nanotechnology field was the creation of 3D DNA crystals 
for use as macromolecular scaffolds28. The purpose was to aid in structure determination using 
X-ray diffraction by bypassing the time-consuming step of crystallizing the macromolecule. 3D 
DNA crystals would ideally be able to act as scaffolds to strategically place and align 
macromolecules. The macromolecules would then be held in place with limited mobility and 
therefore be integrated as part of the crystal lattice. To date, there are currently two main 3D 
DNA crystal designs that have been determined by X-ray diffraction and have been used as 
scaffolds for guest molecules: the non-canonical crystals20, first described by Dr. Paukstelis, and 
the tensegrity triangle17. Both designs have solvent channels running throughout the crystals that 
permit the incorporation of guest molecules. Though the use of DNA crystals as molecular 
scaffolds for the structure determination of proteins has yet to be achieved, the tensegrity triangle 
has been used for the organization of fluorescent dye 29, and the non-canonical crystals have been 
used as macromolecular sieves for proteins 27 and as containers for enzyme catalysis 26,30. 
The non-canonical DNA crystal is composed of a 13 nucleotide oligonucleotide, 
d(G1G2A3C4A5G6C7T8G9G10G11A12G13),  that self-assembles in the presence of divalent cations  
to form hexagonal unipyramidal crystals 20,31. Interactions between 13-mers occur in two regions 
of base pairing: a B-form duplex between C4-G9 of two strands, and a parallel-stranded 
noncanonical motif between G1-A3 and G10-A12 of two other strands (Figure 1.1A). Previous 
studies suggested that the Crick-Watson pairing between C4-G9 occurs only upon the addition of 
divalent cations, and the assembly into higher molecular complexes facilitated by the 
noncanonical pairs also occurrs rapidly after Mg2+ addition31. G13 is the only nucleotide in the 
3 
crystal structure that does not form base pairing interactions, and it is disordered in all of the 
crystal structures we have solved. G13 is not necessary for crystallization, and its apparent 
disorder is due in part to its positioning within a series of solvent channels that run through the 
crystal. These solvent channels run parallel and perpendicular to the six-fold symmetry axis 
within the crystal, and make it possible to add additional nucleotides and other groups to the 3' 
end of the oligonucleotides without disrupting crystallization31 (Figure 1.1B). 
The crystal lattice formed by the 13-mer is not limited to the sequence described in 
Figure 1.1A. Variants referred to collectively as complementary versions of the 13-mer 
oligonucleotide contain sequences changes made to the B-form duplex region. A screen was 
generated of all possible self-complementary B-form duplex sequences and some of these 
complementary oligonucleotides crystallized into the same crystal lattice structure as the 13-mer. 
The sequence changes largely play a role in crystallization speed. Different complementary 
oligonucleotides mixed together form a heterogeneous crystal. In order for the heterogeneous 
crystal to form, the B-form duplex region forms first with the proper Crick-Watson base pairing, 
Figure 1.1. A model 3D DNA crystal. A. Secondary structure interactions formed from 
crystallographically identical DNA 13-mers. Four strands are colored differently to highlight Watson-Crick 
interactions in the helical region, and non-canonical base pairs in the interlayer junction region. B. The 
interactions between 13-mers results in a crystal lattice that contains solvent channels that run through the 
length of the crystal both parallel to (left) and perpendicular to the six-fold symmetry axis (right). The G13 
phosphates from two strands are circled in red, showing that these nucleotides are adjacent to one another 
and oriented into the solvent channels. 
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and then propagation of the B-form duplex regions would take place using the non-canonical 
region31.  
The ability of the 13-mer to propagate crystallization in the presence of divalent cations 
also allows these crystals to undergo layer-by-layer assembly. Crystal macroseeds are able to 
resume crystal growth when incubated with newly added DNA 13-mer oligonucleotides. These 
oligonucleotides self-assemble a new shell layer around the crystal core to create a core-shell 
crystal30. The oligonucleotides in either the core or the shell can be functionalized with a variety 
of molecules. The growth of a new layer on the 13-mer crystal has been shown with the 
incorporation of oligonucleotides functionalized with a fluorescent guest molecule, creating a 
fluorescent layer. The ability to incorporate oligonucleotide with different functionalization 
group at each layer allows opportunities for creating multifunctional biomaterials.  
DNA crystals and other nucleic acid based architectures have several potential limitations 
for their use in nanotechnological applications. First, most DNA constructs are composed of 
relatively short DNA duplexes that are prone to thermal denaturation. While no studies have 
systematically examined thermal stability of DNA crystals, a number of studies of DNA tile and 
origami architectures have found that thermal denaturation in solution depends on a number of 
factors, including average duplex length, geometry, and crossover density32,33. Further, because 
DNA is polyanionic, most DNA crystals require relatively high concentrations of monovalent 
and/or divalent cations for crystallization and post-crystallization stability17,20,31. The high cation 
concentration may also limit potential applications if accessory or guest molecules are not 
compatible with these cation concentration. Finally, DNA crystals must be resistant to nucleases 
present in cellular environments or serum to be useful as delivery vehicles or for in vivo sensor 
and diagnostic applications.  
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Another limitation is a significant portion of the DNA crystal design field has been 
focused on altering and understanding properties in existing designs29,31,34, or identifying new 
DNA motifs to expand structural diversity35,36. Inherently, these approaches interrogate the 
nanoscale properties of the crystals in the form of intermolecular contacts that enable 
crystallization. Significantly, very little has been done to control macroscopic properties of 
existing DNA crystals. One of the fundamental macroscopic properties of crystals are their 
morphologies, or crystal habits. Morphology plays an important role in nano-bio interactions; the 
morphology of a drug delivery device can influence distribution and uptake37. The ability to 
modulate the final morphology of crystals has the potential to diversify 3D DNA crystal 
applications by offering a customizable feature to the design process. 
The main goal of my research had been to address limitations of DNA crystals in order to 
increase the viability for downstream applications. We enhanced the durability of  the 13-mer 
crystal using nonspecific chemical cross-linkers to form inter-strand cross-links38. Additionally, 
we also improved the durability of the 13-mer crystal via the formation of polymerized dopamine 
(PDA)-coat on the surface of the crystal. As a result, the 13-mer’s thermal stability was 
increased, it was stable at low magnesium concentration (<10 mM) and its half-life in a 
biological condition was increased. We addressed the static morphology of the 13-mer by adding 
“poisons” to the crystallizing conditions that hinder the growth of the crystals in specific 
directions. The poisons were truncated versions of the 13-mer that we designed and we were able 
to use them to predictably control the morphology 39. The work that has been done to improve 
the 13-mer for downstream application has increased the half-life of the crystals in the presence 
of guest molecules such as doxorubicin (DOX). DOX is commonly used to test the efficiency of 
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drug delivery devices into cells or animals models. Other DNA nanostructures have incorporated 
doxorubicin via intercalation40,41, and now we can add DNA crystals onto this list.  
Even though the idea of DNA crystals started the DNA nanotechnology field, 3D crystals 
are relatively new arrivals that have not been extensively explored. My research centers on 
expanding the utility of 3D DNA crystals by focusing on how to improve the infrastructure 
through enhancing the durability and modulating the morphology. The methods utilized here can 
























Chapter 2: Enhancing Durability of Three Dimensional Crystals 
Using Chemical Crosslinker 
 *This chapter is derived from “Zhang, D. & Paukstelis, P. J. Enhancing DNA Crystal Durability through Chemical 
Crosslinking. ChemBioChem 17, 1163–1170 (2016).” 
 
Chapter 2.1: Introduction  
 
The ability of a structure to maintain its stability at least until it can carry out its purpose is 
an important aspect of any engineering process. Data collection for macromolecular crystals is 
most often performed at cryogenic temperatures to minimize radiation damage, however, the initial 
cooling process can lead to lattice disorder that negatively impacts diffraction. Chemical 
crosslinking has been used as a general strategy to improve the stability of protein crystals42,43. In 
a number of cases, non-specific glutaraldehyde crosslinking has been successfully employed to 
generate covalent bonds between neighboring proteins that allow the crystal to resist changes in 
temperature or solution conditions to improve diffraction44. Similarly, photo-crosslinking has been 
used to enhance the thermal stability of DNA origami constructs45, while site-specific formation 
of DNA catenanes using specialized oligonucleotides have been successfully used to enhance the 
stability of DNA origami structures46.  
Figure 2.1. Nornitrogen mustard chemical crosslinking mechanism between two guanines. 
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Bis(2-chloroethyl)amine (nornitrogen mustard; NOR) is a DNA alkylating agent capable 
of interstrand crosslinking47,48.  It is the primary active agent in cyclophosphamide, and like other 
nitrogen mustards, it preferentially alkylates the N7 position of purines, with guanosine having a 
higher crosslinking efficiency than adenosine47,49–51. With two functional groups capable of going 
through the aziridinium intermediate, NOR reactivity can result in mono- or dialkylation, with the 
latter potentially leading to intra- or interstrand crosslinks (Figure 2.1). NOR has a limited half-
life in aqueous solution, estimated to be on the order of minutes52, due to reactivity in water to 
form bis(2-hydroxyethyl)amine (Figure 2.2). To our knowledge, the interstrand crosslinking 
potential of NOR or other nitrogen mustards within DNA crystals has not been examined.  
The 13-mer crystal was an ideal candidate to test NOR crosslinking. The parallel-
stranded non-canonical motif of the (Figure 1.1 A) provides a rich source of purines in close 
proximity to one another to improve chances for dialkylation. Additionally, this is a region where 
the different helical layers interact in the crystals. G13 is an additional site that can be alkylated. 
It does not form any base-pair interaction within the crystal lattice and is positioned within the 
Figure 2.2. Incomplete nornitrogen bialkylation. A. The aziridinium intermediate reacts with water. 
B. Depurination of guanine due to instability of alkylated guanine. 
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solvent channel. Therefore, it is flexible and has the mobility to interact with other purines in 
close proximity, including another G13 nucleotide.  
My work demonstrates that chemical crosslinking of these DNA crystals with NOR results 
in their increased thermal stability, decreased cation dependence, and reduced nuclease sensitivity. 
Gel electrophoresis of crosslinked crystals suggests that crosslinking can occur at several sites, 
leading to multiple crosslinked species. We mapped the crosslinking site in the most abundant of 
these species and found that the unpaired G13 residue appears to be a primary crosslinking site. 
We further demonstrate that higher-molecular weight crosslinks are decreased in crystals that lack 
G13, and that the G13 crosslinks are required for enhancing crystal thermal stability. This chemical 
crosslinking strategy may be broadly applicable to all types of DNA architectures. 
Chapter 2.2: Results and Discussion  
 
Chapter 2.2.1: Nornitrogen mustard forms interstrand crosslinks within the DNA crystal 
 
Gel electrophoresis of dissolved crystals following incubation with NOR at 4 clearly 
demonstrated interstrand crosslinking within the crystals. This was judged by the presence of 
higher molecular weight bands relative to the uncrosslinked control in both radioloabeled and non-
radiolabeled samples (Figure 2.3). Up to four higher molecular weight products were observed, 
along with one species with slightly lower electrophoretic mobility than the uncrosslinked control 
that is presumably the result of DNA alkylation events that do not lead to interstrand crosslinks. 
Furthermore, the number of higher molecular weight bands was directly correlated to the NOR 
concentration (Figure 2.3C). Crosslinking efficiency measured by densitometry of SYBR Gold 
showed up to ~60% of the product was present in the dimeric, trimeric, and tetrameric species 
(Figure 2.3A). Over multiple experiments we observed higher apparent crosslinking efficiency 
when samples were stained (Figure 2.3A) than when radiolabeled (Figure 2.3B). Though the 
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reason for this is not entirely clear, it is possible that crosslinks at positions near the 5' end leads to 
decreased labeling efficiency through inhibition of the kinase reaction, similar to observations for 
other 5'-protected DNAs53. Because of the short half-life of NOR in solution, we performed two 
sequential treatments to achieve the best overall crosslinking efficiency at 4°C (Figure 2.3 A, B).  
Crystals that had undergone the crosslinking procedure were also subjected to x-ray 
diffraction, using the same cryoprotection methods as previously described31. The unit cell 
parameters, space group, and diffraction limits were nearly identical to the previously determined 
crystal structure. Electron density maps showed minimal differences. There was additional 
electron density associated with the N7 position of G9 and G10 (Figure 2.4). This may be the result 
of alkylation events, though the density was not sufficient to model. Importantly, these results 
indicated that crosslinking did not disrupt or change the overall crystal structure.  
Figure 2.3. Polyacrylamide gel analysis of crosslinked crystals. Control 13-mer (C) and NOR-treated 13-
mer crystal (CL) stained with A. SYBR Gold, or B. after 5' 32P radiolabeling.  SYBR staining consistently 
showed higher apparent crosslinking efficiency than radiolabeling. C. SYBR Gold stain of 13-mer crystal 
(CL) treated with Lane 1, 250 mM NOR at 4˚C; Lane 2, 100 mM NOR at 4˚C; Lane 3, 50 mM NOR at 




Chapter 2.2.2: Crosslinking enhances crystal thermal stability 
 
We first examined how the crosslinking procedure impacted the thermal stability of the 
crystal by determining dissolution temperatures based on UV absorption. Each dissolution 
experiment used at least 15 crystals in a single cuvette to ensure sufficient signal. We confirmed 
that all crystals sank to the bottom of the cuvette and were out of the direct light path. The average 
dissolution temperature for the control samples was 41.1 °C, and the average dissolution 
temperature for the treated crystals was 46.4 °C, both from four independent trials (Figure 2.5A). 
Interestingly, the initial phase, 20 ̊C - ~35˚C, dissolution for the crosslinked crystals was flatter 
than for the control crystals. Absorption gains became apparent at ~35 °C for the crosslinked 
Figure 2.4. Electron density of NOR-treated crystals. Sigma-A-weighted 2Fo-Fc (blue; 1 σ contour) 
and Fo-Fc (green/red; 2 σ contour) electron density associated with nucleotides G9 and G10. These 




crystals, whereas the absorption began to increase immediately for the control samples. This 
suggested that the crosslinked crystals remained intact over this initial temperature range.  
 
 
To confirm that the crosslinked crystals could remain intact at higher temperatures, we 
made visual observations of the crystals incubated at 33, 35 and 37 °C. At all three elevated 
temperatures we examined, the control crystals dissolved from the exterior inward, leading to a 
progressive decrease in size, while initially retaining an overall hexagonal unipyrimidal 
morphology (Figure 2.6). In all cases the crosslinked crystals showed lower apparent linear 
reduction rates (Figure 2.5B-2.5D). At 33°C the control crystals had modest stability, disappearing 
at an observed rate of ~6.6% hr-1. In contrast, the treated crystals did not dissolve at an appreciable 
Figure 2.5. NOR-treatment enhances crystal thermal stability. A. Dissolution temperature determination. 
Control (black) or crosslinked (red) crystals were heated to determine the crystal dissolution temperatures 
by UV absorption. In all four independent trials the crosslinked crystals had higher dissolution 
temperatures as well as a more shallow initial dissolution phase. Control and crosslinked crystals were 
also examined at elevated isothermal temperatures: B. 33˚C, C. 35˚C, D. 37˚C. Dashed lines indicate that 
crystals dissolved between these time points. The terminal time points were not used for determining the 
linear reduction rates. Each time point is an average measurement from 5 crystals with error bars 
representing standard deviation. 
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rate when measured in hours, with crystals remaining intact after 7 days. The overall size reduction 
over the 7 day period was 15.3%, consistent with flat first phase of the curve in the dissolution 
experiments (Figure 2.5A). At 35°C and 37°C the control crystals dissolved more quickly, with 
reduction rates of 20.3 and 20.6% hr-1, respectively. The treated crystals also had higher dissolution 
rates at these temperatures, but these changes were more modest at 4.6 and 8.0% hr-1 at 35°C and 
37°C, respectively.   
Chapter 2.2.3: Crosslinking decreases cation dependence 
 
Our previous work determined that the 13-mer crystals required divalent cation 
concentrations of 50-200 mM Mg2+ for crystal assembly and stability31. To determine if 
crosslinking impacted the cation dependence we compared crosslinked and control crystal stability 
by incubating them in  the cations that support crystal growth (Mg2+ and Ca2+) at various 
concentrations, with the lower limit chosen near the reported total blood plasma concentrations54. 
In the Mg2+ conditions the crosslinked crystals showed enhanced tolerance to the decreased cation 
concentrations, even at the lowest concentrations tested (Figure 2.7A). At 1 mM Mg2+ the control 
crystals shrank at a rate of 9.2% hr-1. At the same concentration the crosslinked crystals initially 
showed an overall average 12.1% reduction in size after 24 hours, after which they maintained a 
Figure 2.6. Crystal dissolution at elevated temperature. Crystals incubated at elevated temperature dissolve 
from the exterior toward the interior. 
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constant size. At 5 and 10 mM Mg2+ the control crystals dissolved more slowly, with an apparent 
half-life of ~6 days. At these concentrations the crosslinked crystals did not shrink appreciably 
over the course of the 8 day experiment. A similar pattern was seen in the Ca2+ conditions (Figure 
2.7B). Over four days, the control crystals had an average overall 80% reduction in size at 3 mM, 
a 50% reduction at 10 mM and 10% reduction at 50 mM. The crosslinked crystals showed only 
minimal reductions (maximum 5.7% overall at 10 mM) in all three conditions after 4 days.  
All DNA crystals presumably require relatively high cation concentrations for stability due 
to the high density of negatively charged phosphate groups in the oligonucleotide backbones. 
These cation requirements can severely limit potential applications of DNA crystals55. The 
covalent interactions introduced by NOR crosslinking appear to sufficiently rigidify the lattice to 
overcome the repulsive forces associated with the decreased ionic strength and any concomitant 
changes in Debye length. However, we cannot rule out other factors including cation sequestration 
as a result of crosslinking, or the positive charge imparted on the N7 position upon alkylation as 
other sources for lattice stabilization.  
Figure 2.7. Crosslinking decreases divalent cation requirements. Control (black) and crosslinked (red) 
crystals were examined under three different A. Mg2+ concentrations, or B. Ca2+ concentrations at room 
temperature. In all cases, crosslinked crystals shower lower reduction in size, even at the lowest divalent 
cation concentrations. The high standard deviations for controls crystals in 5 mM Mg2+ and 10 mM 
Mg2+ at day 6 and 7 are the result of one or two crystals completely dissolving.  
15 
Chapter 2.2.4: Crosslinking provides resistance to DNase I and enhances stability in cell culture 
media 
 
With the growing interest of using nanoscale DNA architectures for cellular applications, 
there is a need for maximizing the durability of DNA constructs under conditions that mimic 
cellular and extracellular environments. Several studies have examined the resistance of DNA 
origami structures to nucleases in solution or those present in serum32,56. Though these assemblies 
were more resistant to nucleases than free plasmid DNA, they were still degraded rapidly by DNase 
I32, while incubation in fetal bovine serum (FBS) also led to rapid degradation of DNA assemblies 
without pre-treatement of the serum to inactivate nucleases56. Because DNA constructs are 
susceptible to nucleases in these settings, we examined the impact of NOR crosslinking on DNase 
I degradation of the 13-mer crystals, and their survivability in tissue culture medium.  
Control and crosslinked crystals were incubated with different amounts of DNase I and the 
change in crystal sizes were monitored (Figure 2.8A). We note that DNase I has reduced activity 
at elevated Mg2+/Ca2+ conditions57, however, performing the experiments at high divalent cation 
concentrations allowed us to separate the divalent cation stability and nuclease resistance between 
control and crosslinked crystals. The control crystals shrank linearly at rates that correlated with 
the amount of enzyme, with half-lives ranging from ~3 days (1 U) to ~1.5 days (10 U).  Crosslinked 
crystals, however, showed small reductions in size, with the only visible damage being pitting on 
the surfaces of some crystals. No single condition resulted in more than a 20% reduction in size 
after 7 days (Figure 2.8A).  
Next, we examined the stability of crystals incubated in DMEM tissue culture medium  
supplemented with 10% FBS and 10 mM Mg2+ (Figures 2.8B & 2.8C). Control crystals were 
rapidly degraded in this cell culture medium with an apparent half-life of ~20 minutes (Figure 
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2.8B). The crosslinked crystals showed significantly higher durability under these conditions. 
After 2 days the crosslinked crystals had not decreased in size, though in some cases the sharp 
crystal edges had begun to round. The crystals began to dissolve between 2 and 3 days and were 
still present after 7 days at an average of ~20% their original size. 
Previous studies implicated FBS as the main source of nucleases responsible for the 
degradation of DNA nanostructures in various culture mediums56,58. Therefore, we examined 
crystal durability in 100% FBS containing 10 mM Mg2+ (Figure 2.9). Control crystals degraded 
rapidly, though they were still visible after 7 hours. Crosslinked crystals showed little change after 
20 hours. Interestingly, the greater longevity of control crystals in FBS alone than in DMEM+FBS 
suggests that some components in DMEM (likely the added salts) may enhance degradation of the 
crystals.  
Figure 2.8. NORtreatment enhances nuclease resistance and longevity in tissue culture medium. A. Control 
(black) and crosslinked crystals (red) were incubated with varying amounts of DNase I and the crystal size 
was monitored over time. B. Size reduction of control crystals incubated in DMEM (10% FBS, 10 mM 
Mg2+)at 22˚C.  C. Size reduction of NOR-treated crystals in the same conditions as (B). The large error 
associated with the measurement at day 4 was due to two of five crystals dissolving completely between 
day 3 and 4.  The remaining three crystals were used for the day 7 measurement. 
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Chapter 2.2.5: G13 is involved in the formation of dimeric crosslinked species 
 
Because each DNA strand in the crystal is identical, if crosslinks occurred between 
identical nucleotides of two strands only dimeric higher order species would be observed. The 
appearance of multiple higher molecular weight species in the gel analysis (Figure 2.3) indicated 
that NOR could form interstrand crosslinks between at least two different nucleotides in the 
oligonucleotides. We took advantage of the lability of N7 alkylation in hot piperidine to attempt to 
determine the nucleotides involved in interstrand crosslinking. We focused on the dimeric species 
as we could obtain sufficient material following gel purification.  
We compared piperidine cleavage patterns between dissolved crosslinked crystals, solution 
crosslinked oligonucleotides, and gel purified dimeric species from crosslinked crystals (Figure 
2.10) with guanosine positions determined from DMS-modified 13-mers. Though the 13-mer 
oligonucleotide contains 7 guanosine nucleotides, we could only resolve the 6 largest radiolabeled 
Figure 2.9. Comparison of treated and untreated crystals in FBS+10 mM Mg2+. Untreated crystals at the 0 
hour and 7 hour time point are shown in (A), while the NOR-treated crystals at the same time points are 
shown in (B).  
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products, as piperidine cleavage at G2 would result in a single nucleotide monophosphate, and 
cleavage at G1 would remove the 5' 32P label entirely. Thus, we could not interrogate crosslinking 
at positions G1 or G2. For each of the crosslinked samples we observed all six products, suggesting 
that in both solution and in the crystal, all of the guanosine nucleobases 3' of G6 were accessible 
to NOR alkylation. For oligos crosslinked in solution, very little of the full-length or 12 nucleotide 
product were present, indicating that all positions of the unstructured oligonucleotide in the 
absence of Mg2+ 31 were susceptible to NOR alkylation, and that a majority of oligonucleotides 
were alkylated one or more times. For the dissolved crosslinked crystals, the full-length 13-mer 
was the most prominent band (66.5% of quantifiable product), followed by cleavage at G9 (8 
nucleotide product; 11.5%), G6 (5 nucleotide product; 5.9%), and G13 (12 nucleotide product; 
8.6 %). There were no higher molecular weight products, indicating that piperidine cleavage had 
removed all of the crosslinked species (Figure 2.3). Interestingly, for the gel purified dimer from 
the crosslinked crystals, the full-length 13-mer was still the most prominent product (51.2%), 
followed by cleavage at G13 (19.7%). The largest difference in truncated products between the 
dissolved crystals, solution crosslinked 13-mer, and the purified dimer was the accumulation of 
this 12 nucleotide product. This suggests that G13 – which is disordered in the crystal structure – 
is primarily involved in interstrand crosslinking in the dimer, though we could not exclude other 
positions, such as G9 or G6, as additional potential crosslinking sites.   
The abundance of the full-length 13-mer in the piperidine-cleaved dimer was surprising. 
We anticipated that the purified dimer would show little to no 13-mer product following piperidine 
cleavage because at least one nucleotide in each monomer would be alkylated and cleaved into 
fragments smaller than 13-mers. Control experiments confirmed that the dimeric band was intact 
following purification (Figure 2.11), suggesting that the appearance of the 13-mer was not the 
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result of spontaneous cleavage or crosslink reversal. A possible scenario that explains this result is 
that one or more of the sites responsible for interstrand crosslinking in the dimeric species is 
insensitive to piperidine cleavage. Piperidine-resistance has been documented for other DNA 
alkylating agents59, and this has been attributed to alkylation at sites other than purine N7's, 
including N2 of guanosine, and N6 or N3 of adenosine. Formation of G-A and A-A intra- and 
interstrand crosslinks have been reported for other nitrogen mustards50. 
Though it is disordered in the crystal structure, two G13's residues are in close proximity 
based on the strand arrangement (Figure 1.1A) and the positions of G13 phosphates in the crystal 
structure. Using simple modeling in which the complete G13 nucleotides of the two strands were 
randomly positioned, we examined positions that would be consistent with the 5 Å arm length of 
Figure 2.10. G13 is a primary site for NOR-crosslinking. Lane 1, Crosslinked 13-mer crystals treated with 
piperidine. Numbers on the left indicate nucleotide sizes of the final products. Numbers to the right of the 
bands indicate the percentage of product based on densitometry. Lane 2, piperidine cleavage of solution 
crosslinked 13-mer oligonucleotides; Lane 3, gel purified crosslinked dimer band from NOR-treated DNA 
crystals following piperidine cleavage;  Lane 4, DMS-modified 13-mer piperidine cleavage products as a 
G-ladder control; Lane 5, control 5' labeled 13-mer. The relative amount of the 12 nt product in Lane 3 
compared to Lane 1 suggests that G13 is a primary crosslinking site in the purified dimeric species. 
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the nitrogen mustards. Because of their proximity, many different conformations would bring two 
G13's N7 positions within this 5 Å distance. Several other positions were consistent with this 
distance restraint, assuming no local structural variations as a result of crosslinking. These included 
potential interstrand crosslinks between G13(N7)-G1(N2), G13(N7)-G2(N7), G13(N7)-A3(N3), 
and G13(N7)-G10(N7). Neither G6 or G9 were in a position to form interstrand crosslinks based 
on N7 positions.  
Chapter 2.2.6: G13 enhances crystal crosslinking and is required for increased thermal stability. 
 
DNA oligonucleotides lacking G13 crystallize under the same conditions as the 13-mer 
and have identical crystal morphology. This allowed us to test the functional importance of G13 in 
crosslinking and crystal stability. Gel analysis following NOR treatment showed that the 12-mer 
crystals had reduced crosslinking efficiency as judged by the overall amount of crosslinked product 
Figure 2.11. Dimeric crosslinked species is intact prior to piperidine cleavage. Lane 1, purified dimeric 
band from crosslinked crystals after piperidine cleavage; Lane 2, dissolved crosslinked crystals; Lane 3, 
purified dimeric band from crosslinked crystals without piperidine treatment. The numbers on the right 
show nucleotide sizes. 
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and the lack of significant higher molecular weight species beyond the dimer (Figure 2.12A). We 
then examined the dissolution temperatures of 12-mer crystals (Figure 2.12B). The dissolution 
temperature of the control 12-mer crystals (41.2 °C) was consistent with our results from the 
control 13-mer crystals (41.1 °C; Figure 2.5A), indicating that removing G13 did not compromise 
the baseline stability of the crystal lattice. Consistent with the decreased overall crosslinking in the 
absence of G13, there was no increase in the thermal stability of the crosslinked 12-mer crystals 
(Figure 2.12B), but rather a reduced dissolution temperature compared to the control. This suggests 
that some alkylation events may destabilize portions of the crystal lattice, and that the interstrand 
crosslinking afforded by G13 can overcome such destabilizing events. Together with the piperidine 
cleavage experiments these results show that the unpaired G13 residue is involved in interstrand 
crosslinks, that it is responsible for enhancing crosslinking beyond the dimer, and that those 
crosslinks are necessary for enhanced thermal stability.  
Figure 2.12. G13 is necessary for efficient crosslinking and enhanced thermal stability. A. Gel analysis of 
12-mer crystal (lacking G13) crosslinking. 12 and 13 are labeled 12-mer and 13-mer oligonucleotides, 
respectively. 12X and 13X are dissolved NOR-treated crystals. The 12-mer displays lower crosslinking 
efficiency and fewer higher molecular weight products than the G13-containing crystals.  B. Dissolution 
experiments of 12-mer crystals that are uncrosslinked (black) or NOR-treated (red).  
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Chapter 2.3: Conclusion 
 
Here we have developed a simple chemical crosslinking strategy for improving the 
durability of 3D DNA crystals. Our results clearly demonstrate that treating crystals with 
nornitrogen mustard leads to increased thermal stability, decreased cation dependence, and 
increased nuclease resistance. The utility of DNA constructs in biological and non-biological 
settings is highly dependent on their versatility under different environmental conditions, and our 
results suggest chemical crosslinking is one method to achieve that versatility. Additionally, though 
we did not see enhancements in x-ray diffraction following crosslinking, it is possible that this 
may be useful as a technique for improving DNA crystal diffraction, similar to protein crystal 
crosslinking. This study has also demonstrated the importance of the unpaired G13 nucleotide for 
crosslinking efficiency and thermal stability in this model crystal, though it is not yet clear how 
general this feature would be for other DNA constructs. Overall, this technique is a simple single 
step treatment to form covalent linkages that improve durability without the use of costly 
nucleotide derivatives. 
Chapter 2.4: Materials and Methods  
 
Chapter 2.4.1: Oligonucleotide synthesis, purification and crystallization  
 
The oligonucleotides were synthesized on an Expedite 8909 (PerSeptive Biosystems) with 
reagents from Glen Research (Sterling, VA) using standard phosphoramidite synthesis and 
deprotection. Oligonucleotides were gel purified and electroeluted as previously described20 before 
dialysis against deionized water.  
The oligonucleotides were crystallized by sitting drop vapor diffusion. 2 µL of DNA solution (200 
µM) and 1 µL crystallization buffer (10% 2-methy-2,4-pentanediol, 120 mM magnesium formate, 
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50 mM lithium chloride) were incubated against 300 µL of crystallization buffer in the reservoir. 
Trays were incubated overnight at 22º C and provided 5-10 crystals per well. 
Chapter 2.4.2: Crosslinking and gel analysis  
 
Crystals were removed from the crystallization tray and placed in a glass soaking dish and washed 
with 100 µL of 120 mM magnesium formate for 5 mins to remove free DNA. The crystals were 
then transferred to 120 mM magnesium formate with 250 mM freshly added nornitrogen mustard 
(Sigma-Aldrich, St. Louis, MO) and soaked >12 hours at 4 ºC. The buffer was removed and 
crosslinking step was repeated a second time in freshly prepared buffer for another 12 hours at 4 
ºC. Crosslinking of oligonucleotides in solution was performed by addition of 0.5 M nornitrogen 
mustard to 200 µM of oligonucleotide solution and incubated at 4˚C. 
Interstrand crosslinks were identified by polyacrylamide gel electrophoresis. Crosslinked crystals 
were prepared by soaking in 100 µL water for 5 mins before being transferred to 4 µL of water 
that was heated to 95˚C to dissolve the crystals. Crystals to be radiolabeled were transferred to 38 
µL of water and dissolved by heating prior to adding 5 µL 10X T4PNK Reaction Buffer, 2 µL T4 
polynucleotide kinase (New England Biolabs), 5 µL of 50 pmol [γ-32P] ATP (PerkinElmer) and 
incubated at 37˚C for 30 mins. Samples were incubated for 5 mins at 95˚C prior to loading onto a 
20% denaturing polyacrylamide gel (19:1).  
Chapter 2.4.3: Crystal stability measurements 
 
Dissolution profiles were obtained on a Cary100 Bio UV-VIS spectrophotometer using a 0.2°/min 
temperature ramp with absorbance at 260 nm recorded every minute. Overall crystal stability was 
measured by visual observations of crystals sizes recorded using a stereo microscope with attached 
CCD camera. The percent reductions over time were determined by measuring the change of 
24 
crystal diameter across the hexagonal base. For all of the stability assays, a minimum of 5 crystals 
were used with average values reported. To test thermal stability, crystals were soaked in 120 mM 
magnesium formate for 5' to remove any excess NOR and then transferred to fresh 120 mM 
magnesium formate solution and incubated at various temperatures. For divalent ion concentration 
stability, the crystals were initially transferred to drops containing 100 µL buffer solution at the 
final divalent ion concentration as a wash step before being transferred to a fresh 100 µl drop and 
incubated at 22˚C. For DNase I stability tests, crystals were soaked in 120 mM magnesium formate 
to remove any free oligomers and NOR before being transferred to 100 mM magnesium formate, 
20 mM calcium chloride solution with the addition of varying concentrations of DNase I to a final 
volume of 15 µL. Crystals were incubated at 22˚C.  Similarly, crystals were washed in 10% 
magnesium formate before being transferred into either Dulbecco Modified Eagle Medium 
(DMEM) (supplemented with 10% FBS and 10 mM magnesium formate) or 100% FBS 
(supplemented with 10 mM magnesium formate)  at 22˚C.  
Chapter 2.4.4: Piperidine cleavage 
 
DMS G-ladder control was generated by incubating radiolabeled DNA in DMS reaction buffer (50 
mM sodium cacodylate pH 8.0, 1 mM EDTA, 1 mM dimethyl sulfate) at room temperature for 5 
mins. The reaction was terminated by addition of stop buffer (1.5 mM sodium acetate pH 7.0, 1.0 
M β-mercaptoethanol). Piperidine cleavage was carried out essentially as previously described60. 
Briefly, radiolabled DNAs were incubated at 95 ˚C in the presence of 1 M piperidine for 30'. 
Samples were dried under vacuum before being redissolved in gel loading buffer before being 
resolved on 20% (19:1) PAGE. 
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Chapter 2.4.5: Gel purification of crosslinked species 
 
The radiolabeled crosslinked treated crystals were separated on a 16 x 22 cm 20% polyacrylamide 
gel. The gel portion containing the dimeric species was identified by autoradiography, excised, 
minced, and soaked in water overnight at room temperature with gentle agitation. The solution 
was filtered and the supernatant was ethanol precipitated overnight with glycogen as a carrier. The 














Chapter 3: Enhancing Durability of Three Dimensional Crystals 
Using Polydopamine 
 
Chapter 3.1: Introduction  
 
The deposition of polydopamine (PDA) on/into the 13-mer crystal was explored as an 
alternative and more passive way, relative to NOR treatment38, to enhance the durability of the 
crystal lattice. The concept was derived from 3,4-dihydroxy-L-phenylalanine (DOPA) secreted 
from mussels61,62. The DOPA plays an important role in the mussels’ ability to attach to almost 
any wet surface. The PDA derived from DOPA can deposit on a variety of surface types63 (both 
inorganic and organic materials, and some polymer surfaces) and form a PDA coat. This PDA 
coat has primarily been utilized as a single step, solution based technique for simple layer-by-
layer (LbL) assembly. Currently, this type of LbL has primarily been used to form a layer for 
functionalization61,63,64 or for capsule formation65.  
Dopamine is capable of self-polymerization via the formation of the self-cyclized 5,6-
dihydroxyindole (DHI) (Figure 3.1A)66–68. First, the hydroxyl groups on dopamine are oxidized 
to form dopaminequinone. Then, the dopaminequinone goes through intramolecular cyclization 
to become leukodopaminechrome. Oxidation and rearrangement of leukodopaminechrome forms 
5,6 dihydroxyindole (DHI). DHI is the precursor for polymerization; DHI can interact with either 
DHI or dopamine to form polymerized dopamine coat69. Self-polymerization can occur either 
through the covalent or noncovalent pathway (Figure 3.1B). In the covalent pathway, DHI 
polymerizes with a second DHI forming a 2,2-linked DHI-DHI dimer. Then, the DHI-DHI dimer 
forms a link with dopamine between the C-4 of DHI and C-5 of dopamine. The non-covalent 
pathway involves DHI and dopamine stacking on top of one another via ionic, cation-pi, pi-pi, 
quadrupole-quadrupole or hydrogen bonding.  
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The PDA can act as a reinforcing network to hold the crystal lattice in place with several 
potential benefits for PDA over the method previously described (from Chapter 2). First, the 
PDA coat is opened for surface modification via simple catechol chemistry61,63,64. The purpose of 
the surface modification is to functionalize the core that the PDA deposited onto. In other 
studies, this has allowed tailoring for specific applications such as drug delivery70 and acting as a 
biosensor71,72. Importantly, dopamine and the PDA pose no toxicity to the cell65, which may not 
be the case for NOR-treated crystals. Furthermore, guanines need to be present within close 
Figure 3.1.  Pathways for dopamine polymerization. A. Self-cyclization of dopamine into 5,6-
dihydroxyindole (DHI). B. Self-polymerization of DHI and dopamine can occur via the covalent pathway 
or the non-covalent pathway. 
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proximity of one another and be in the right orientation in order for NOR to be effective, while 
dopamine can be deposited on a wide variety of surfaces. Additionally, the PDA coat could 
enhance the durability of the crystal lattice without modifying the underlying structure. NOR 
provides an effective method for stabilizing 3D DNA crystal via chemical modification of the 
lattice structure38, but PDA coat formation provides an alternative when chemical modification 
to the crystal framework is unwanted or unfavorable to the application.   
The two main factors we examined that can affect dopamine polymerization and can be 
easily manipulated in the lab are pH and temperature. By altering the pH and/or temperature, we 
could modulate the extent of polymerization and therefore control the shell thickness of the PDA 
coat. Based the on polymerization chemistry, neutral and basic conditions are optimal for 
polymerization61, while acidic conditions hinder polymerization. The alkaline environment aided 
in the deprotonation of the hydroxyl groups on dopamine and oxidized dopamine into dopamine-
quinone, the precursor for dopamine polymerization.  
In addition to the pH and temperature, we analyzed dopamine polymerization in the 
presence of high magnesium, which is normally required for the stability of DNA crystals. The 
catechol group in dopamine can coordinate metal ions (Figure 3.2) and play a role in the 
mechanical properties of DOPA in mpf-1 mussels proteins73, while also impacting oxidation rate 
Figure 3.2. Schematic of metal complexations between catechol and group two metals. 
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74. Oxidation of dopamine leads to the formation of dopamine-quinone, which is an important 
intermediate for dopamine polymerization (Figure 3.1A). The presence of high metal ion 
concentration can decrease the pKa of the hydroxyl groups, allowing deprotonation to occur at a 
lower pH. Once the hydroxyl group becomes fully deprotonated, there will be excess electron 
density on the catechol, making it more susceptible to oxidation (Figure 3.2). 
My work here shows PDA deposition on the crystals can enhance overall crystal stability 
by increasing thermal stability and stability at low divalent cation concentrations. We applied the 
polymerization condition to the 13mer crystals we previously characterized31 (Figure 1.1) and 
saw a direct effect between pH and temperature, and PDA coat formation. We examined the 
ability of the PDA coat to stabilize 13mer crystal at low magnesium concentration and at 
elevated high temperatures, as previously done with the NOR-treated crystals38. We found that 
the PDA coat increased the stability of the 13mer crystals in both conditions. The ability of the 
PDA coat to stabilize the crystal lattice is the first time PDA had been used as a framework to 
preserve the integrity of crystallized macromolecules.  
Chapter 3.2: Results and Discussion   
 
Chapter 3.2.1: Evaluating polydopamine formation  
 
First, we explored PDA formation when pH and/or temperature were varied. We tested 
PDA formation in 120 mM magnesium formate at three temperatures (4˚C, 22˚C and 37˚C), and 
varied the pH between 5.5 and 8.5. Dopamine forms black-brown precipitate when 
polymerization has occurred, allowing for facilitated visual identification69 and detection at OD 
600. The results showed that the maximum polymerization varied across the different pH and 
temperature tested (Figure 3.3). At all three temperatures tested, optimal formation was at pH 
7.5, followed by pH 8.5, with minimum dopamine polymerization at pH 5.5, 6.5 and no buffer 
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conditions. The pattern of dopamine formation at different pH showed that the high magnesium 
concentration did not significantly change the PDA formation from what was seen previously63,65 
at pH 8.5 where dopamine polymerization was optimal at neutral or basic pH. Additionally, 
dopamine formation plateaus off after 4-5 hours, consistent with previous results.  
There was a general positive correlation between PDA formation and increased pH. The 
increased PDA formation with increasing pH agrees with previous reports that basic pH would 
allow greater oxidation of the hydroxyl groups, thereby increasing PDA formation as the 
availability of DHI becomes higher (Figure 3.1). Surprisingly though, it was expected that pH 
8.5 would have been the most polymerized63,65, we observed this at pH 7.5. There was no 
difference between the sodium cacodylate (NaCaCo) and the Tris HCl buffer used ruling out 
dependence in buffer composition. Overall, the PDA formation pattern at the different pHs was 
consistent across the different temperatures tested at 4˚C, 22˚C, and 37˚C. Although there was a 
general increase at OD 600 as the temperature was increased from 4˚C to 22˚C, and from 22˚C to 
37˚C. The increased polymerization as the temperature increased may be the result of faster rate 
of oxidation of the hydroxyl groups which would had also increased the availability of DHI for 
polymerization.  
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Chapter 3.2.2: Polydopamine coat formation on 13mer crystal.  
 
Next, we treated the 13-mer crystals with dopamine from each of the previous tested 
PDA formation condition, pH 5.5 – 8.5, and temperatures 4˚C and 22˚C. Crystals treated in the 
optimal PDA formation conditions of pH 7.5 and 8.5 developed a darkly coated surface (Figure 
3.4). Crystals at low pH conditions, 5.5 and 6.5, did not show a PDA coat. Moreover, the crystals 
treated at 22˚C clearly showed a darker PDA coat than those treated at 4˚C. The pattern of coat 
formation on the crystals was consistent with the PDA formation results in the absence of the 
crystals (Figure 3.3) indicating the maximum polymerization seen in the absence of the crystals 
correlated to dopamine deposition on the crystals.  
Figure 3.3. Polydopamine (PDA) formation measured at OD 600 at (A) 4˚C, (B) 22˚C and (C) 37˚C. 
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No PDA coat was formed or observed at pH 5.5, at 4˚C and 22˚C, and pH 6.5, at 4˚C. 
The lack of PDA coat formation did not mean that dopamine had no effect on the crystal lattice. 
It has been shown at acidic pH, dopamine can form adducts with guanine or adenine75. To test 
this, we dissolved the dopamine-treated crystals and ran them on a denaturing gel to assess the 
presence of higher molecular weight oligomers. The gel showed no higher molecular weight 
bands and no unusual shifts in the bands compared to the untreated control crystal (Figure 3.5). 
This indicated there was no observed modifications made to the oligomers of the crystal lattice at 
acidic pH and at the other conditions.  
 
Figure 3.4. Polydopamine (PDA) coat on 13-mer crystal. 
Figure 3.5. Acrylamide gel of PDA-coated 13-mer crystals. 1. 13-mer crystals alone. Crystals were 
treated with dopamine at 2. 10 mM NaCaCo pH 5.5; 3. 10 mM NaCaCo pH 6.5; 4. 10 mM Tris HCl 
pH 7.5; 5. 10 mM Tris HCl pH 8.5; and 6. No buffer. There were two crystals in each well. 
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Chapter 3.2.3: Stability of polydaopmine-coated crystals at low magnesium concentration    
 
We further evaluated whether the PDA coat would enhance durability at low magnesium 
concentration and found that the PDA coat varied in its ability to stabilize the crystals in 10 mM 
magnesium formate depending on the original PDA polymerization condition (Figure 3.6). 
Crystals at 22°C and pH 6.5, or with no buffer were the most effective in stabilizing the crystal 
lattice. The crystals incubated with dopamine at pH 5.5 at both 4˚C and 22˚C dissolved by day 2. 
This was consistent with the low levels of polymerization seen previously indicating little to no 
PDA coat formation to help stabilize the crystals. Dopamine treatment of crystals at pH 5.5 
actually ended up decreasing the stability of the crystal lattice: the non-treated crystals lasted 
longer, with an 80% reduction in diameter at day 7 (Figure 2.7A). This could be due to the effect 
of the low pH environment, which had been shown to cause crystal degradation. Meanwhile, the 
crystals from the other conditions showed varied levels of degradation; the crystals were either 
pitted, had decreased in diameter or both. In this case, the pH that promoted the highest PDA 
formation did not provide the highest level of crystal stabilization.  
The highest level of stabilization was achieved at pH 6.5 and no buffer, which had lower 
PDA formation compared to the more basic pHs conditions (Figure 3.3). One possible 
explanation for this was the low PDA formation could have been the result of slower rate of 
formation, allowing the dopamine monomers or low molecular weight PDA to penetrate into the 
solvent channels before a complete PDA coat formation occurred resulting in a more extensive 
PDA network.  Additionally, the extensive network may be more effective in chelating or 
trapping magnesium ions during the polymerization process resulting in a reserve of cations 
when the crystals were moved to lower magnesium conditions.  
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Figure 3.6. Stability of PDA-coated crystals in 10 mM magnesium formate. PDA coat formation on crystals 
at A. 4˚C and B. 22˚C. Above the columns are the pH conditions for PDA deposition onto the crystals, and to 
the left of the columns are days the images were taken. Scale bars, 70 µm. 
Figure 3.7. Stability of crystals with PDA coat formation at 22˚C incubated at 30˚C. Above the columns 
are the pH conditions are the pH conditions for PDA deposition onto the crystals, and to the left of the 




Figure 3.8. Stability of PDA-coated crystals at 37˚C. Stability of crystals with PDA coat formation  A. at 
4˚C incubated at 37˚C and B. at 22˚C incubated at 37˚C over time. Above the columns are the pH 
conditions are the pH conditions for PDA deposition the crystals, and to the left of the columns are days 
the images were taken. Scale bars, 70 µm. 
36 
Chapter 3.2.4: Thermal stability of polydopamine-coated crystals   
  
In addition to evaluating the PDA-coated crystals at low magnesium concentration, we 
evaluated the thermal stability of the PDA-coated crystals at 30˚C and 37˚C. Similar to 
crosslinking results, we saw improvement in the thermal stability of the coated crystals compared 
to the non-coated crystals. Impressively, when the crystals were incubated at 30˚C, all the coated 
crystals were still present by day 16, except for the coated crystals at pH 5.5. Although most of 
the coated crystals have degraded in quality to some extent, yielding a mixture of empty “husks” 
(presumed to be PDA networks, ~ 20%), partial filled dopamine shells (~70%) or intact crystals 
(~10%). Crystals originally at 22˚C pH 8.5 fared the best, showing no degradation at day 2 while 
the crystals in the other conditions had begun to cracked, pitted or degraded (Figure 3.7). For the 
crystals at 37˚C, crystals initially treated with dopamine at 4˚C pH 8.5, 22˚C pH 7.5 and 22˚C pH 
8.5 showed the best stability as they were unchanged at day 1 (Figure 3.8), compared to non-
coated crystals that were gone within a day (Figure 2.5D). By day 7, the majority of the crystals 
had left behind an empty husk, except a handful of crystals from conditions 22˚C pH 7.5 and pH 
8.5 while crystals at pH 5.5 were completely gone by day 1.  
The conditions that led to the best improvement in thermal stability correlated to the 
highest maximum PDA formation measured at slightly basic conditions and 22˚C. This was in 
contrast to the magnesium results where dopamine formation on the crystals at pH 6.5 had shown 
to provide the best stabilization. This indicated intrinsic differences in how the PDA coat 
influenced crystal stability in different ways. The higher dopamine polymerization may have 




  Both the PDA coat and the NOR-treatment38 had increased the overall durability of the 
crystals, but they differ in the degree they strengthen the crystals in each stability test. The 
stability of the crystals treated in the optimal PDA formation condition at 10 mM magnesium 
formate was similar to the NOR crystals, with both treatment methods showing indefinite 
stability compared to their respective controls. On the other hand, there were mixed results with 
the thermal stability data when evaluating which method was better. At 30˚C, the PDA-coated 
crystals had showed significant degradation or had completely dissolved (Figure 3.7) while the 
NOR-treated crystals had remained indefinitely stable at 33˚C (Figure 2.5B). However, at 37˚C, 
the NOR-treated crystals were gone within 24 hours (Figure 2.5D) while the optimal dopamine-
treated crystals were still present in day 7 (Figure 3.8B).  
While we know the PDA coat enhanced the overall durability of the crystal lattice, it is 
unclear exactly how the PDA coat was stabilizing the crystal lattice. The catechol group of 
dopamine and its derivatives may had played a role due to their ability to form a metal complex 
with magnesium. Magnesium plays a vital role in the stability of the DNA crystals by shielding 
the repulsion due to the closely packed negatively charged DNA backbone. The PDA coat could 
have acted as a net, trapping the excess magnesium that would otherwise be absent, and this 
would have contributed to the overall stability of the crystal.  
Chapter 3.3: Conclusion 
 
The application of the PDA coat on 3D DNA nanostructures provides an alternative, non-
covalent method of improving the durability of 3D DNA crystals. We showed that changing the 
pH and temperature can modulate the rate of formation and the maximum formation reached 
which will in turn effect on how effective the PDA was in improving the durability of the DNA 
crystals. The optimal conditions significantly improved thermal stability and durability at 
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decrease low magnesium concentration. For the first time, we show here that PDA formation can 
act as a stabilizer of macromolecular structures.   
Chapter 3.4: Materials and Methods  
 
Chapter 3.4.1: Oligonucleotide synthesis and purification  
 
The oligonucleotides were ordered from IDT (Integrated DNA Technologies) or synthesized on 
an Expedite 8090 DNA synthesizer (PerSeptive Biosystems) with reagents from Glen Research 
(Sterling, VA) using standard phosphoramidite synthesis and deprotection. Oligonucleotides 
were gel purified and electroeluted as previously described20 before dialysis against deionized 
water.  
Chapter 3.4.2: Crystallization  
 
Oligonucleotides were crystallized by sitting drop vapor diffusion. 2 µL of 200 µM 13 
nucleotide oligomer and 1 µL water were added to the sitting drop, followed by 1 µL of 
crystallization buffer (10% 2-methy-2,4-pentanediol, 120 mM magnesium formate, 50 mM 
lithium chloride). Drops were equilibrated against 300 µL of crystallization buffer. Crystal trays 
were incubated overnight at 22˚C.  
Chapter 3.4.3: Polydopamine formation  
 
1.5 mL of 10 mM Sodium cacodylate pH 5.5, 10 mM Sodium cacodylate pH 6.5, 10 mM Tris 
HCl pH 6.5, 10 mM Tris HCl pH 7.5, 10 mM Tris HCl pH 8.5, and no buffer solutions with 10 
mM dopamine HCl and 120 mM magnesium formate in 1.7mL Eppendorf tubes were incubated 
overtime at 4˚C, 22˚C and 37˚C.  Samples were measured at OD 600 at the designated time 
points.  
Chapter 3.4.4: Polydopamine deposition on crystals  
 
39 
10 uL of 2X PDA formation (except with 60 mM magnesium formate instead of 120 mM) 
solutions above were added into 10 uL of 120 mM magnesium formate in 24 well crystal trays 
containing crystals and incubated overnight.  
Chapter 3.4.5: Crystal stability measurements 
 
PDA-coated crystals were transferred to fresh 100 uL aliquots of the equivalent buffer solutions 
that the crystals were initially in to wash away excess PDA. The crystals were then transferred to 
15 uL of the same buffer for the stability experiments. Overall crystal stability was measured by 
visual observations of crystal sizes, recorded using a stereo microscope with attached CCD 
camera. The percent reductions over time were determined by measuring the change of crystal 
diameter across the hexagonal base. For all of the stability assays, a minimum of 5 crystals were 
used with average values reported. For divalent ion concentration stability, the crystals were 
initially transferred to drops containing 100 µL buffer solution at the final divalent ion 

























Chapter 4: Incorporation of Doxorubicin in 3D DNA Crystals  
 
Chapter 4.1: Introduction  
 
Doxorubicin (DOX) or Adriamycin® is one of the most effective anticancer treatment on 
the market and has been approved for used for more than 30 years. Derived from daunorubicin, 
an antibiotic produced by Streptomyces peucetius, it was found to be an effective treatment 
against acute leukemia and lymphoma76 in the 1950s. Since then, DOX has been categorized as a 
broad-spectrum anti-cancer treatment, effective against a wide variety of solid tumors, multiple 
myeloma, and Hodgkin’s and non-Hodgkin’s lymphoma77,78.  
 The exact mechanism of DOX’s therapeutic action is unclear. One of the most 
accepted mechanisms is the interference with topoisomerase II (Top II)79. Top II relaxes DNA 
supercoils formed during DNA transcription by cutting a double helix and passing another 
double helix strand through it, and resealing the cut duplex afterwards. DOX interferes with this 
process by stabilizing the Top II complex after cutting, preventing the resealing with double 
helix, and therefore stalling DNA replication.  
 Despite DOX’s high efficacy, DOX has poor target selectivity, which can lead to 
adverse side effects, such as cardiotoxicity80. One resolution to this issue is the encapsulation of 
DOX within a delivery device targeted towards the cancer site. In addition to circumventing 
adverse side effects, this will increase target selectivity, increase cellular uptake, and increase the 
half-life of DOX.81,82 
There are drug delivery vehicles made from lipids83,84, polymers85, and metallic  
nanoparticles86. Devices made from lipids are in the form of liposomes, spheres with lipid bilayer 
membranes. Polymeric devices are largely based on poly(D,L-lactic-co-glycolic acid) (PLGA) 
polymers. Each of the material as a drug delivery device has their own advantages and 
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drawbacks. The drawback of liposomes are slow release from the lipid vehicles, thereby 
lowering their effectiveness 87,88. Polymeric devices are rapidly cleared from the blood stream, 
therefore decreasing the effectiveness of the drug89. For metal nanoparticles, the drawback is the 
accumulation of metal particles in the body which can lead to toxicity86.  
DNA nanostructures are a prospective class of nano-delivery devices with several distinct 
advantages90.  The diverse architectures that can be generated allows them to be tailored to 
specific applications9,39. For instance, rod shaped nanoparticles have better cellular uptake than 
spherical shape nanoparticles37, therefore rod shaped DNA nanostructures can be specifically 
produced for this function. Another benefit of DNA nano-delivery devices is they are 
biocompatible and do not exhibit cell cytotoxicity or immunogenicity24,91,92. Additionally, the 
delivery of DOX via DNA origami has been shown to be effective against cancer cells already 
resistant against DOX41. DOX, especially, is known to induce multi-drug resistance in cancer 
cells93,94 thus efficacy against drug resistant cancer cells will address one of the leading problems 
in cancer treatment.  
Several DNA nanostructures have already been evaluated as drug delivery devices for 
DOX, such as the triangle-shaped DNA origami24 and DNA icosahedra nanocages25. These DNA 
nanostructures have been shown to be successful in delivering DOX to cells or animal 
models24,25. DOX mainly associates with these DNA nanostructures via intercalation41,95–97; the 
disadvantage of incorporation via intercalation alone is that it limits the loading capacity of the 
DNA container. The limited loading capacity can be solved by increasing the density or 
sequestering the drugs in other spaces. DNA crystals provide a unique solution to this problem. 
Crystals would allow DOX to be incorporated within the solvent channels as well as via 
intercalation, thereby increasing the loading capacity.   
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Here, we assessed a 3D DNA crystal31 composed of self-assembled 13 nucleotide long 
oligomers as a potential DNA nanostructure for drug delivery.  We quantified the crystal’s 
ability to incorporate and retain DOX using microscopy and fluorimetry and confirmed 
incorporation of DOX at high concentrations within the crystal lattice. Moreover, we improved 
the retention of DOX within the DNA crystal by transitioning the crystal lattice state into a gel 
state. This was achieved by partial destabilization of the crystal lattice either by soaking at high 
DOX concentration and/or lowering the magnesium concentration. The ability to limit diffusion 
of the DOX prematurely is important for restricting exposure of the drug to non-target sites 
before it reaches its destination, thereby also increasing the load of the cargo when the target is 
reached.  
Chapter 4.2: Results and Discussion  
 
Chapter 4.2.1: Incorporation of doxorubicin into 13mer crystals at room temperature 
 
Doxorubicin was introduced into the solvent channels of the 13mer crystals via diffusion. 
We submerged the crystals in DOX containing solution ranging from 1.68 µM to 430 µM, and 
monitored them for up to 4 days. Both the NOR-treated crystals and non-treated crystals were 
used in order to compare the effect of crosslinking on the durability of the crystal lattice during 
DOX exposure. DOX contains an anthraquinone chromophore (Figure 4.1A) that gives the 
molecule a bright red coloration (Figure 4.1B) which aids visualization of DOX underneath the 
light microscope. We immediately observed bright red coloration within the crystals underneath 
the light microscope after 1 day, demonstrating successful DOX incorporation. Additionally, 
there was a positive correlation between the intensity of the red coloration and the DOX 
concentration the crystals were submerged in (Figure 4.2). The correlation between the DOX 
concentration and color intensity suggested the amount of DOX intercalated into the lattice was 
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concentration dependent. This was further supported by the observation that the crystals 
degraded as the DOX concentration increased, suggesting higher level of DOX intercalating into 
the lattice also induced instability.   
Crosslinking the crystals mitigated the degradation due to DOX exposure. In all the 
conditions, the NOR crosslinked crystals exhibited better stability in the presence of DOX 
relative to the non-treated crystals (Figure 4.2). For instance, the crosslinked crystals at 1.68 µM 
and 6.72 µM showed little or no reduction in size by day 4, while the non-treated crystals had 
Figure 4.1. Structure of A. anthraquinone and B. doxorubicin.  
Figure 4.2. Light microscope images of crystals soaked in DOX at room temperature. We added the non-
treated crystals (Control) and NOR-treated (NOR) crystals to buffer (10 mM Tris HCl pH 7.5 and120 mM 
magnesium formate) with DOX, concentrations above the columns, at day 0 (D0). Scale bars, 70 µm. 
45 
reduced in size significantly. The non-treated crystals at 1.68 µM showed an average percent 
reduction of 17.65% and became rounded, a sign of degradation, while the crosslinked crystals 
showed a lower average percent reduction of 4.33%. The crosslinked crystals also showed a 
lower average percent reduction at 6.72 µM of 6.72% while the non-treated crystals showed an 
average of 58.32% reduction. The trend continued at higher DOX concentration of 26.87 µM, 
107. 5 µM and 430 µM where the non-treated crystals were more degraded or completely 
degraded than the crosslinked crystals by day 4. Interestingly, the trend in degradation broke for 
the crosslinked crystals at 430 µM DOX. At this high concentration, the crosslinked crystals 
became dark red globular structure instead of becoming completely degraded, while the non-
treated crystals left behind skin-like shells.  
Chapter 4.2.2: Incorporation of DOX into 13mer crystals at 4˚C 
 
The NOR crosslinked and non-treated crystals were additionally soaked at 4˚C to 
evaluate whether the decrease in temperature would mitigate the degradation experienced at 
room temperature (Figure 4.3). It was found that soaking the crystals at 4˚C had a positive effect 
on crystal stability. For example, at room temperature, the non-treated crystals and the NOR 
crystals at 107.5 µM were completely dissolved by day 3 (Figure 4.2), except for crosslinked 
crystals at 430 µM DOX, but at 4˚C, the crystals in both conditions were still present at D6 with 
minimal degradation. Rounding of the crystals was still seen for both crystal sets at a higher 
concentration of 480 µM DOX.  
An interesting observation was the lack of a clear border on the edge of the crystals 
between the crystals at 480 µM and the crystals at lower concentrations below 107.5 µM (Figure 
4.4A). When the crystals without borders were broken, they smeared like jelly instead of 
fragmenting as the crystals normally do (Figure 4.4B), prompting us to refer to these as “gel” 
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crystals. When we transferred these gel crystals to a new buffer, the DOX did not visibly diffuse 
out, in contrast to the non-gel crystals. This gel state was seen only at higher concentrations of 
DOX, above 136.10 µM. In addition, varying the concentration had an effect on how fast the gel 
state was reached and how likely the crystals were to retain their original morphology (Figure 
4.3B). Non-treated crystals incubated at DOX concentrations between 322.5 µM and 136.10 µM 
were able to achieve the gel state with no degradation and retained the hexagonal morphology.  
Interestingly, the crosslinked crystals at DOX concentration above 136.10 µM achieved this state 
earlier, by day 1. The non-treated crystals on the other hand reached this state anywhere between 
day 3 and day 9.  
47 
 Figure 4.3. Light microscope images of crystals soaked in DOX at 4˚C. Non-treated crystals (Control) and 
NOR-treated (NOR) crystals to buffer (10 mM Tris HCl pH 7.5 and120 mM C2H2MgO4) with DOX, 
concentrations above the columns, at day 0 (D0). A. Crystals were incubated DOX concentration between 
0 and 480 µM. B. Crystals were incubated at more narrow DOX concentration range 136.10 µM- 322.5 
µM, and 0 µM. Scale bars, 70 µm. 
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Chapter 4.2.3: Effect of magnesium on doxorubicin in corporation  
 
We hypothesized that the gel state was the result of instability of the crystal lattice, 
because the gel state was only achieved at higher concentration of DOX. At higher DOX 
concentration, there would be more DOX intercalating into the crystal, leading to disruption in 
the stacking interactions, thereby destabilizing the overall lattice structure. Normally, instability 
of the crystal lattice would result in degradation until nothing was left, as seen with the crystals 
at DOX concentration below 107.5 µM, but the instability caused by high DOX intercalation led 
to the formation of the gel state.   
To test this, we explored the correlation between magnesium concentration and the 
transition into the gel state (Figure 4.5). Magnesium plays an essential role in the stability of 
DNA nanostructures; the positive charge shields the negatively charged DNA phosphate 
backbone in order for DNA backbones to be in close proximity to one another. Therefore, an 
Figure 4.4. Light microscope images of gel and non-gel crystals. A. Gel crystals without clear borders 
(left) and non-gel crystals with clear borders (right), and B. broken gel crystals.  
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increase in magnesium concentration would strengthen the lattice backbone interaction, and a 
decrease would weaken the lattice contact and facilitate the intercalation of DOX. We incubated 
the NOR 13-mer crystals (B7) and its complementary crystals (A2, A3 and B6), where there are 
permutations in the Crick-Watson base-pair (Figure 4.5A), in 322.5 µM DOX, in magnesium 
concentration ranging from 50 mM to 200 mM magnesium formate. 
 
 
Figure 4.5.  Effect of magnesium on formation of gel crystals. A. Sequences of oligonucleotides used in 
this study. Sequences are vertically aligned, with positions in red indicating sequences differences relative 
to the 13-mer DNA. B. Effect of different C2H2MgO4 concentrations on DOX incorporation. Light 
microscopes images of different complementary 13-mers at different C2H2MgO4 concentrations. Listed left 
of the images are the different 13-mers. The different C2H2MgO4 concentrations are listed above the images. 
Scale bars, 70 µm. 
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We observed an inverse relationship between the level of DOX incorporated and the 
magnesium concentration. The level of DOX observed within the crystals gradually dropped as 
the magnesium concentration was increased; the crystals lost their gel state and a clear band was 
seen along the edge of the crystals (Figure 4.5B).  For the 13-mer (B7) crystal set, we saw a 
gradual decline in the intensity and penetration of the DOX as the magnesium concentration 
increased. The complementary crystals showed a similar pattern but oddly, the gel state was 
reached at a higher magnesium concentration than B7. This suggests that the differences in the 
Crick-Watson base pairs may play a role in the stability of the crystal lattice and therefore how 
easily DOX intercalates into the crystal.  
In conclusion, the gel state was affected by the stability of the crystal lattice as shown by 
the trend between DOX incorporation and magnesium concentration. The information allowed us 
to understand how the gel state was achieved and how to better control the onset of the gel state. 
The ability to control the onset of the gel state would be beneficial, because it appeared to have 
higher DOX incorporation than the non-gel state, allowing us to increase the load capacity of the 
13-mer crystal.  
Chapter 4.2.4: Loading capacity and retention of doxorubicin inside 13-mer crystal 
 
We used confocal microscopy to confirm and further evaluate DOX incorporation and 
retention. The crystals at lower DOX concentration, 107.5 µM and below, showed that the 
incorporation of DOX was positively correlated to the initial DOX concentration the crystals 
were soaked in; the higher the DOX concentration, the higher the fluorescent intensity. NOR 
crystals incubated in 6.72 µM and 1.68 µM DOX for four days showed that the NOR crystals 
incubated 6.72 µM had a higher intensity than the ones soaked at 1.68 µM (Figure 4.6 C,D). 
Also, NOR crystals in 107.5 µM DOX at 4˚C had a higher intensity than 26.87 µM (Figure 4.7 
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B,C). Crosslinking the crystals also increased the intensity relative to the non-treated crystals. 
NOR crystals incubated at 107.5 µM at room temperature for 3 hours and 107.5 µM DOX 
incubated at 4˚C had a higher intensity than their non-crosslinked counterparts in the same 
conditions (Figure 4.6 A,B and 4.7 A,B).   
Interestingly, the non-gel crystals and the gel crystals showed different apparent levels of 
incorporations. Z-stack images of the non-gel crystals showed DOX was incorporated throughout 
the crystal (Figure 4.6 and 4.7). In contrast, the gel crystals, which had visually showed higher 
level of incorporation based on the intensity of the red coloration, showed uneven DOX 
distribution by fluorescence, including large areas within the center of the crystals that were not 
fluorescent (Figure 4.8). Importantly, the lack of intensity does not necessarily correlate to the 
absence of DOX. Quite the opposite, DOX experiences self-quenching at high concentration of 
>10 µM 98. Fluorimetry data further supported that gel crystals had a higher loading capacity for 
DOX than the non-gel crystals. The fluorescent intensity of the dissolved gel crystals of similar 
dimensions was six-fold higher than the non-gel crystals (Figure 4.9). The high fluorescent 
Figure 4.6. Confocal microscopy images of non-gel crystals. The table to the right shows the initial 
intensity of the crystals, and the percentage of intensity that remained after 7 days for A. non-treated and B. 
cross-linked crystals soaked in 107.5 µM DOX for 3 hrs at RT, and cross-linked crystals soaked in C. 6.72 
µM and at D. 1.68 µM incubated for 4 days. 50 µm. Day 7 image has been enhanced. 
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intensity of the gel crystals seen with the fluorimeter confirmed that the lack of intensity seen 







Figure 4.7. Confocal microscopy of DOX diffusion of non-gel crystals. Table shows initial intensity of the 
crystals and percentage of intensity that remained at day 0, 2 and 9 for A. non-treated and B. NOR crystals in 
107.5 µM DOX incubated at 4˚C for 7 days, and C. NOR crystals in 26.87 µM DOX at 4˚C for 7 days. Scale 
bars, 50 µm. Day 2 and day 9 images has been enhanced to show fluorescence.  
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Figure 4.8. Confocal microscopy images (Z-stack) of NOR-treated gel crystals. The crystals were incubated 
at 322.5 µM (A & B) and 136.10 µM (C & D). Scale bars, 50 µm. 
Figure 4.9. Fluorimeter measurement of DOX-incorporated crystals. Fluorescent intensity of ~25 dissolved 
1. Non-gel crystals, 2 and 3. gel crystals and 4. polydopamine-treated crystals. 
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In addition to the high load capacity, the gel crystals retained DOX better than the non-
gel crystals. When both crystals were transferred to fresh buffer, we saw that the DOX in the 
non-gel crystals appeared to diffuse out under the light microscope while the gel crystals retained 
the DOX. This result is interesting, because the gel crystals may have had better retention due to 
instability of the crystal lattice. This could be the result of lattice deformation, which resulted in 
sealing off the solvent channel and trapping the DOX inside, hence, improving DOX retention.  
The retention of DOX inside the non-gel crystals was evaluated using confocal 
microscopy, and the retention of DOX inside the gel crystals was evaluated using fluorimetry. 
The same crystals imaged before using confocal microscopy were imaged 7 days later in fresh 
buffer solution. The majority of the crystals showed more than 90% decrease in intensity (Figure 
4.6). A second set of crystals that were incubated with DOX at 4˚C  (Figure 4.7) showed most of 
the diffusion occurred early on, with an average reduction of 40% in intensity by day 2, and 70% 
reduction in intensity by day 9. The non-linear diffusion of the DOX out of crystal could indicate 
different levels of intercalation within the lattice.  
Fluorimetry data showed that the DOX diffused out of the gel crystals slower than the 
DOX diffused out of the non-gel crystals. An average of 25 gel crystals were incubated at 4˚C 
overtime and samples were collected from the supernatant at day 0, day 3, day 7, day 10 and day 
14 (Figure 4.10). At the end time point, we dissolved the crystals and collected the samples for 
measurement. The gel crystals did not indefinitely prevent the DOX from diffusing from the gel 
crystals, but it did reduce the amount that diffused out of the crystal lattice relative to the non-gel 
crystals. At day 3, an average of 26.2% of the DOX had escaped from the gel crystals. The total 
DOX lost plateaued off considerably afterwards, with an average of 43.62% lost at day 10 and 
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47.66% at day 14. Overall, the crystals retain on average, 52.34% of their original load by day 
14.  
Chapter 4.2.5: Layer-by-layer assembly on doxorubicin-incorporated crystals  
 
We performed layer-by-layer (LBL) assembly on the DOX-incorporated crystals to 
evaluate whether the addition of DOX will affect the assembly process. The non-gel and gel 
crystals were layered with 13-mer oligomers (with and without fluorescein attachment at 3’end) 
and polydopamine (PDA). A new layer formed on both crystal types. The new crystal layer 
differed in structure depending on how ordered the core crystal was. An ordered layer formation 
occurred on the non-gel crystals similar to non-DOX crystals; the DOX did not affect the ordered 
assembly of the new layer (Figure 4.11). On the other hand, the new layer on the gel crystals 
Figure 4.10. Measurement of DOX diffusion out of ~25 gel crystals over time. We collected samples from 
the supernatant over time and measured the intensity, shown here as the percent of the total intensity 
measured. The horizontal line indicates the intensity of the ~25 gel crystals dissolved after 14 days as a 
percent of the total intensity measured.  
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resembled an agglomeration of the oligomers whether than an ordered crystal layer (Figure 
4.12). It was not surprising that the state of the new layer reflected the level of order of the core 
since LBL assembly with oligomers relies on order incorporation into the existing framework of 
the crystals. The disordered crystal layer on the gel crystals may be a representation of how the 
core crystal was ordered and confirmed that the DOX had destabilized the ordered crystal lattice. 
Subsequently, dopamine was successfully deposited on the gel crystals, creating a dark PDA coat 
similar to what was seen with non-DOX crystals.  
 
Figure 4.11. LbL assembly on non-gel crystals. Light microscope images of DOX-incorporated crystals in 
fresh crystallization buffer with A. no additional layer added, B. layered with 13-mer and C. layered with 13-
mer-fluorescein. Scale bars, 70 µm. 
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Next, we evaluated whether the additional layer on the non-gel crystals and gel crystals 
would improve retention of DOX within crystals. The oligomer layer on the non-gel crystals did 
not have any effect on the retention. The lack of retention could be attributed to the diffusion of 
the DOX outpacing the layer formation or since the new layer is forming via ordered assembly, 
the solvent channels are continued from the core, thereby providing a route for the DOX to 
diffuse out.  Additionally, the new PDA did not improve DOX retention of the gel crystals. The 
percent of DOX retained (~70%) after seven days was equivalent to the non-PDA gel crystals. 
Oddly, the amount of DOX measured in the PDA coated gel crystals were significantly lowered 
(~50 %) than the non-PDA versions (Figure 4.13). The DOX could have been stuck to the PDA 
coat, which did not dissolve at higher temperatures. The additional layer did not improve 
retention, but the demonstrability of LBL assembly on the non-gel and gel crystals provides the 
opportunity for specific functionalization of the crystal exterior.  
 
Figure 4.12. LbL assembly on gel crystals. Light microscope images of gel crystals in fresh crystallization 
buffer with A. no additional layer added, B, layered with 13-mer and C. layered with 13-mer-fluorescein. Scale 
bars, 70 µM.  
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Chapter 4.3: Conclusion 
 
For the first time, we incorporated doxorubicin, a small drug molecule, into a 3D 
continuous DNA crystal. The 3D DNA crystal contains solvent channels running throughout the 
lattice structure. DOX can be incorporated into the crystal through intercalation and sealed 
within the solvent channels while most other DNA nanostructures incorporate DOX via 
intercalation. The instability caused by the DOX intercalation resulted in the transition of the 
uniform crystal structure into a gelatinous or glass-like structure instead. The solvent channels 
become sealed off and as a result, traps the DOX inside and therefore increasing the loading 
Figure 4.13. Retention of DOX in PDA coated crystals over time. Fluorimetry measurement of 1. Dissolved 
~25 PDA coat crystals at D0; 2. Supernatant after 7 days; 3. dissolved ~25 crystals PDA coat after 7 days. 
Scale bars, 70 µm. 
59 
capacity. The new gel structure increased retention of DOX and loading capacity compared to 
the crystal structure. Future task can focus on exploring the gel states compared to the crystal 
state. Tools such as atomic force microscopy (AFM) can measure the stiffness of a sample99 and 
can be used to compare the difference between the crystal and gel state.  
The DNA crystal is on the path as a drug delivery device or in vivo utilization. The 
loading of DOX into the crystal is simple, no modifications or coupling steps are necessary. 
Furthermore, the ability to grow an additional layer on top of the DOX crystals provides the 
advantage of tethering molecules30 to the surface. The ability for secondary surface 
functionalization can increase target specificity and uptake. The uptake can be further improved 
by the ability to program the morphology of the crystal39. The process of loading a guest 
molecule into the crystals can be expanded to include fluorescent probes for bioimaging or in 
vivo labeling, or cytosine-phosphate-guanine (CpG) sequences to act as an immunostimulant.  
 
Chapter 4.4: Materials and Methods  
 
Chapter 4.4.1: Oligonucleotide synthesis and purification  
 
The oligonucleotides were ordered from IDT (Integrated DNA Technologies) or were 
synthesized on an Expedite 8090 DNA synthesizer (PerSeptive Biosystems) with reagents from 
Glen Research (Sterling, VA) using standard phosphoramidite synthesis and deprotection. 
Oligonucleotides were gel purified and electroeluted as previously described20 before dialysis 
against deionized water.  
Chapter 4.4.2: Crystallization  
 
Oligonucleotides were crystallized by sitting drop vapor diffusion. 2 µL of 200 µM 13 
nucleotide oligomer and 1 µL water were added to the sitting drop, followed by 1 µL of 
crystallization buffer (10% 2-methy-2,4-pentanediol, 120 mM magnesium formate, 50 mM 
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lithium chloride). Drops were equilibrated against 300 µL of crystallization buffer. Crystal trays 
were incubated overnight at 22˚C.  
Chapter 4.4.3: Incorporation of DOX  
 
The crystals were washed in 100 µL of soaking buffer (10 mM Tris HCl pH 7.5 and 120 mM 
magnesium formate) for 5 mins. The crystals were then transferred by nylon loop to 5 uL of 
soaking buffer and 5 uL of DOX (272.2 µM – 960 µM).  
Chapter 4.4.4: Layer-by-layer assembly  
 
DOX crystals were washed in 100 µL crystallization buffer prior to use. DOX were transferred 
by nylon loop to a sitting drop containing 2 µL of crystallization buffer. 1 µL of 175 µM 13-mer 
oligomer supplemented with or without 25 µM fluorescein-labeled 13-mer was then added. The 
sitting drop was then equilibrated against 300 µL of crystallization buffer and incubated 
overnight at 22˚C. 
Chapter 4.4.5: Dopamine Polymerization on DOX crystals  
 
10 uL of 2x of PDA formation solution (10 mM Tris HCl pH 7.5, 60 mM magnesium formation, 
10 mM dopamine HCl) solutions above were added into 10 uL of 120 mM magnesium formate 
in 24 well crystal trays containing DOX crystals and incubated overnight.  
Chapter 4.4.6: Visualization and measurements   
 
Light microscope crystal images were taken of the crystals in the sitting drop on a stereo 
microscope with an attached CCD camera. The fluorescein-incorporated layered crystals were 
imaged with a Leica SP5X confocal microscope. Prior to visualization, crystals were washed in 
100 µL crystallization buffer and then transferred to a 200 µL crystallization buffer on a 35 mm 
glass bottom culture dish with 14 mm microwell. The fluorescein layer was visualized by 
excitation at 488 nm. Z-stack images were collected every 1 µm. Measurements and 3D 
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reconstructions were performed in ImageJ100 and Leica Application Suite (LAS) AF. Intensity 
measurements were the mean intensity of a set region of interest (ROI).  
Chapter 4.4.7: Fluorimeter measurements  
 
~25 DOX gel crystals were transferred to 100 µL soaking buffer and then to 34 µL soaking 
buffer. 4 µL was removed for day 0 (D0) sample and brought up to 100 µL. 4 µL was also 
collected at D3, 7, 10 and 14.  
At the end, the ~25 DOX gel crystals were washed with 100 µL soaking buffer. The crystals 
were then incubated at 37˚C until completely dissolved. Next, the solution was transferred to a 
cuvette and brought up to 100 µL. The sample was read on the FL-4500 Spectrophotometer 
(ROM Vers 4000 05). The excitation wavelength was 488.0 nm and emission was read 520 – 
680 nm. The wavelength with the highest emission was determined and the intensity taken at that 













Chapter 5: Designed DNA Crystal Habit Modifiers 
*This chapter is derived from “Zhang, D. & Paukstelis, P. J. Designed DNA Crystal Habit Modifiers. J. Am. Chem. 
Soc. 139, 1782–1785 (2017).” 
 
Chapter 5.1: Introduction  
 
A significant portion of the DNA crystal design field has been focused on altering and 
understanding properties in existing designs29,31,34, or identifying new DNA motifs to expand 
structural diversity35,36. Inherently, these approaches interrogate the nanoscale properties of the 
crystals in the form of intermolecular contacts that enable crystallization. However, very little 
has been done to control macroscopic properties of existing DNA crystals. 
One of the fundamental macroscopic properties of crystals are their morphologies, or 
crystal habits. The habit often suggests the underlying periodicity and symmetry of the crystal 
lattice, and many crystal forms can have more than one habit type. Crystal habit modifiers alter 
crystal morphology and are commonly used to enhance certain crystal features for particular 
applications101–105, and are important in biomineralization processes106,107. Habit modifiers may 
act in a variety of ways, including thermodynamically by changing surface energies of selective 
crystal faces, or through kinetic changes that may impact prenucleation, nucleation, and 
growth108. A number of models for the mechanism of habit modification for organic and 
biologically-relevant inorganic crystals have been proposed109–112.  However, in most cases, habit 
modifiers are found empirically through selective addition during the crystallization process. 
This had limited predictive power as to how the macroscopic crystal properties may change. This 
is compounded for macromolecular crystals where there are many more weak intermolecular 
lattices contacts necessary for maintaining crystal integrity113      
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Figure 5.2. Relative orientations of the duplex segments and noncanonical base pairs in the 13-mer 
crystal. Duplex regions are overlayed by semi-transparent cylinders. The yellow cylinder spans two 
duplex segments that are coaxially stacked through noncaonical base pairs between 5' (green) and 3' (red) 
nucleotides. The blue cylinder spans a single duplex segment that connects to the two duplexes of the 
yellow cylinder through its 5' nucleotides. Arrows in the image on the left represent the direction the 
terminal nucleotides exit the duplex segments. All duplex helical axes are orthogonal to the c cell axis, 
which positions the 3' nucleotides along the a and b cell axes.  The 5' nucleotides exit the duplex 
segments down the c cell axis. 
Figure 5.1. Sequences of oligonucleotides used. Sequences are vertically aligned, with positions in red 
indicating sequences differences relative to the 13-mer DNA.  F, fluorescein.  
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The high resolution crystal structures of the non-canonical or 13-mer crystals and a 
number of closely related oligonucleotides sequences31 allowed us to examine lattice features 
that could be manipulated to potentially alter the macroscopic properties of the crystals. One 
notable feature was that the hexameric duplex regions were aligned with their helical axes 
orthogonal to the c cell axis (Figure 5.2). This corresponds to the six-fold symmetry axis in the 
hexagonal crystal system, leading to the duplexes being layered perpendicular to this axis while 
being rotated 120º with respect to flanking layers. The ~2 nm spacing between duplexes within 
each layer creates a series of solvent channels that run through the crystal in multiple directions 
(Figure 1.1B). The 5' nucleotides involved in the noncanonical interactions (G1-A3) exit from the 
duplex helical axis down the c axis, while the 3' most nucleotides (G10-G12) extend out of the 
helices along the a and b cell edges (Figure 5.2). This led us to explore the possibility of 
disrupting either the 5' or 3' most nucleotides to influence crystal growth rates along or 
orthogonal to the six-fold symmetry axis. We designed 5' and 3' truncated versions of the 
oligonucleotide that could still form Crick-Watson base pairs with the full-length strands, but 
would be deficient in forming the noncanonical base pairs (Figure 5.1). We reasoned that these 
truncated oligonucleotides, designated ∆5' and ∆3', could selectively 'poison' crystal growth and 
function as crystal habit modifiers.  
Chapter 5.2: Results and Discussion  
 
Chapter 5.2.1: Crystallization of 13-mer with poison oligomers 
 
The poison oligomers were evaluated by adding increasing concentrations of ∆5' or ∆3' to 
crystal drops containing the full-length 13-mer. We observed distinct concentration-dependent 
crystal habit changes from the starting hexagonal unipyrimidal crystal with both poison oligomers 
(Figure 5.3). Addition of the ∆5’ poison resulted in crystals with preferential growth orthogonal to 
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the c cell axis, resulting in a change to a tabular habit (Figure 5.3B). This transition was dependent 
on ∆5’ concentration, with the change discernible at the lowest concentrations tested. At higher 
concentrations, crystals appeared as 2D hexagons, and at even higher concentrations, crystals did 
not grow. Addition of ∆3’ also generated a new set of concentration-dependent crystal habits 
(Figure 5.3C). At low concentrations, crystals appeared as hexagonal pyramids with slightly 
elongated points. With increasing ∆3’ concentration, the elongated points became discernible 
hexagonal growth that developed to form “bow-tie” shaped crystals. At the highest concentrations 
that still gave crystals, the crystals became uniform acicular hexagonal columns. Interestingly, the 
two poison oligomers showed different concentration dependencies. Habit changes were 
significantly more sensitive to presence of ∆5', possibly reflecting a greater affinity between this 
oligomer and the 13-mer, or different propensities for stable incorporation into the lattice. Crystals 
grown in the presence of both ∆5' and ∆3' favored tabular crystal formation until ∆3' concentrations 
were ~20-fold excess, at which time they formed crystals with  intermediate morphologies that 
was also dependent on the relative concentration of 13-mer and poison strands (Figure 5.4). This 
suggests that the addition of both poison oligomers may allow fine-tuning of the crystal shapes.  
 To determine if partial disruption of optimal base-pairing in the non-canonical region 
would act as a crystal habit modifier, G1 was converted to A (13-mer-G1A) or C (13-mer-G1C) 
(Figure 5.1).  The alteration would disrupt base-pairing with G10 and base-stacking with C4 of a 
different strand (Figure 1.1A). The 13-mer crystallized with high concentration of 13-mer-G1A or 
13-mer-G1C yielded tabular crystals similar to 13-mer with ∆5’ (Figure 5.5), although there was 
a difference in the concentration required to achieve the tabular crystals between 13-mer-G1A or 
13-mer-G1C and ∆5’. The 2D tabular crystals formed with ∆5’ were seen only when the poison 
concentration was 100x lower than the 13-mer. The tabular crystals were seen with 13-mer-G1A 
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or 13-mer-G1C when the concentration was 1.5x higher than the 13-mer.  Additionally, the tabular 
crystals was more elongated along the c-axis even with the higher concentration of poisons 
presented and were not flat 2D tabular crystals as it was with the ∆5’ (Figure 5.3). The higher 
concentration of the G1 poisons required to bring about the same morphological changes as the 
∆5’ suggested that the level of disruption in the non-canonical region reflect the intensity of the 
habit modifying effect the poisons would have.  
Several lines of analysis suggested that the ability for ∆5' and ∆3' to function as habit 
modifiers is dependent on their ability to base pair with the 13-mer directly, and/or their propensity 
to be integrated into the growing lattice. Therefore a complementary 13-mer sequence31 with 
alternations made to the Crick-Watson region (Figure 5.1) should show the same habit 
modification trends using poison oligonucleotides with sequences complementary to its duplex 
region (Figure 5.6 A, D, G, J, M and P). The 13-mer complementary sequences have the same 
non-canonical base-pairing regions, but differ in the Crick-Watson base-pairings31. The 
Figure 5.3. Poison oligomers as crystal habit modifiers. The ratios at the top of each corner for B and C 
indicates the relative concentration of the 13-mer (final concentration 100 µM) to the poison oligomer. A. 
Unipyrimidal crystals in the absence of habit modifiers. Relative orientation to unit cell axes is shown. B. 
Tabular habit modification in the presence of increasing concentration of ∆5' poison. C. Acicular or 
columnar habit modification with increasing concentration of ∆3' poison. Scale bars, 70 µm. 
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complementary sequences used were A2 and B6, with A2 having a four-nucleotide sequence 
difference to the B7 13-mer and the B6 having a two-nucleotide difference (Figure 5.1). If the 
truncations alone generated the morphology changes, crystallizing the complementary 
oligonucleotides with their corresponding poisons should result in similar morphological changes 
as the B7 set.  
 
Figure 5.4. Light microscope images of 13-mer crystals grown in the presence of both ∆5’ and ∆3’. The 
ratios indicate the relative concentration of 13-mer to ∆3’ to ∆5’; the final concentration of the 13-mer was 
100 µM. Scale bar, 70 µm. 
Figure 5.5. Light microscope images of 13-mer crystallized in the presence of 13-mer-G1A and 13-mer-
G1C. Scale bar, 70 µm. 
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The A2 and B6 ∆5’ and ∆3’ truncations also acted as crystal habit modifiers on their 13-
mer counterparts similar to B7 poisons (Figure 5.6A, D, G, J, M and P). Both sets of poisons 
likewise showed similar concentration-dependencies as the B7 poisons. Additionally, the B6 set 
generated a similar array of morphology as the B7 set; tabular crystals at low concentration of ∆5’ 
(Figure 5.6 G) and rod crystals at high concentrations of ∆3’ (Figure 5.6 J). On the other hand, the 
A2 set exhibited significantly different morphology pattern. At high ∆3’ concentrations, rounded 
rod-like crystalline structures formed that morphed into rounded hexagonal unipyramid crystals as 
the concentration was decreased until the sharp hexagonal unipyramid formed (Figure 5.6P). 
Furthermore, at high concentrations of ∆5’, spiked sphere crystals with pyramidal tips formed, and 
as the concentration of ∆5’ was lowered, the number of emerging tips decreased and increased in 
size until a single hexagonal unipyramid was formed (Figure 5.6 M).  Overall, A2 and B6 ∆5’ and 
∆3’ did act as crystal habit modifier on their corresponding 13-mer. However, the sequence 
dissimilarity in the Crick-Watson base-pairing region influenced how similar the morphology 
generated was relative to B7. B6 with two-nucleotide difference generated a morphology pattern 




Figure 5.6. Habit modification and cross-reactivity of poison oligomers. Light microscope images of 
13-mer oligomers crystallizes in the presence of their complementary and non-complementary poisons. 
The ratios at the top of each panel indicates the relative concentration of the 13-mer oligomer to the 
poison oligomer. Scale bars, 70 µm.  
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Next, we observed differences in cross-reactivity when using non-complementary poison 
strands (Figure 5.1). ∆3’ showed minimal cross-activity relative to ∆5’ (Figure 5.6 E,F,K,L,Q,R). 
Both (B7 13+B6-∆3’) and (B6 13+B7-∆3’) only showed impacts on crystal quality at high 
concentrations of the poison strands with no clear trends toward the formation of acicular 
crystals (Figure 5.6 E,K). Moreover, B7 and B6 with A2-∆3’ showed minimum to no 
morphological changes at all (Figure 5.6F,L).  The outlier was with A2 and its non-
complementary ∆3’s; hexagon columnar crystals (Figure 5.6Q) formed with B7-∆3’ at high 
concentration; and hexagonal pyramid with elongated points (similar to B7 with low 
concentration of B7-∆3’) with B6-∆3’ at high concentrations (Figure 5.6R).  
Interestingly, the non-complementary ∆5’ poisons did show a trend toward tabular 
crystals with B7-13-mer and B6-13-mer (Figure 5.6) with the exception of A2-13-mer. Although 
the concentration of poisons required for the effect to be visible was at higher concentrations 
relative to the complementary versions. This, and the previously noted differences in 
concentration dependencies of ∆5’ and ∆3’ is most readily explained by their ability to integrate 
into the growing lattice. Because the duplex region is self-complementary, the poison strands can 
base pair with itself (homopaired) or base pair with the 13-mer strands (heteropaired). In the case 
of ∆3’, it is unlikely that homopaired poison strands could be stably integrated into the lattice, as 
the 3’-most residues are necessary for coaxially stacking of duplexes (Figure 5.2). Thus, higher 
concentrations are necessary to achieve sufficient concentrations of heteropaired duplex to 
observe the habit modification effects. Alternatively, both homopaired and heteropaired ∆5' 
species likely could both be incorporated between duplex regions, meaning lower concentrations 
would be required to observe habit modification. This is also consistent with the observation that 
non-complementary ∆5' poison strands can induce tabular habit modification, as they could be 
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incorporated in the homopaired form. As a control, an 11-mer with no complementary sequence 
to B7 was used as a poison to ensure active incorporation into the lattice via base-pairing is 
required to impede growth. The 11-mer did not act as a poison to B7 and its complementary 
sequences or had any effect on the morphology even when the concentration was 2.5x higher 
than the oligomer concentration (Figure 5.7).  
Chapter 5.2.2: X-ray diffraction showed poison oligomers are only habit modifiers 
 
Diffraction studies were consistent with the truncated oligomers functioning as habit 
modifiers and not as more general modifiers of crystal form. Crystals grown in the presence of ∆5’ 
or ∆3’ had similar unit cell parameters and apparent hexagonal space groups from indexing, while 
also having decreased diffraction limits (Figure 5.8). The decreased diffraction limit suggested the 
possibility that the poison strands were being incorporated into the crystal lattice, where they 
would likely cause local structural changes that would decrease lattice order and overall coherent 
diffraction.  
Figure 5.7. Light microscope images of 13-mer crystallized with 11-mer. Scale bars, 70 µm 
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Chapter 5.2.3: Incorporation of poison oligomers  
 
Electrophoretic analysis of washed, dissolved, and radiolabeled crystals showed low-levels 
of an apparent 9 nt species in crystals grown in either ∆5’ or ∆3’ that was absent in crystals grown 
without the poison strands (Figure 5.9). It is unclear why ∆5' appears truncated by a single 
nucleotide, but we have previously observed that the 3' terminal guanosine (G13), which is 
unpaired in the crystal structure, is one of the more labile spots in the crystal (data not shown), and 
this may be exaggerated in the truncated form.  
 The poison incorporated was compared to the percentage of the poisons in the initial 
crystallization condition to determine if there was a correlation between the concentration at the 
initial crystallization conditions and the amount incorporated. The gel analysis of the dissolved 
crystals showed that that the incorporation of the poison within the crystal does not correlate to the 
ratio of the poisons added. The incorporation of the poisons, in terms of the band percentage  
(Table 5.1), did not exceed 25%, and ranged between 4% and 14% , even though the ∆3’ 
Figure 5.8. Diffraction images. A. Representative diffraction image from 13-mer crystals grown in the 
absence of poison strands. B. Diffraction image of a tabular crystal grown in ∆5', and C. diffraction from a 
crystal grown in the presence of ∆3'.  For all images, d represents the detector distance. Unit cell dimensions 
determined from indexing using MOSFLM121 are shown at the top. All diffraction images were collected at 
APS beamline BM-22 (SER-CAT). 
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concentration in the initial condition was 20-fold higher than the ∆5’. The percentage of ∆5’ 
incorporated was higher than the percentage in the initial crystallization condition, and the opposite 
was true for the ∆3’ where the percentage of poison ∆3’ incorporated was lower than the initial 
crystallization condition. This is likely because the concentration required for ∆3’ to exert its habit 
modifying effect was significantly higher than for ∆5’ and that the ∆5’ is more stably incorporated 
into the lattice structure. Interestingly, B6 poison crystal set did not exhibit the same level of 
incorporation as B7 (Figure 5.10). The only low molecular weight band detected was the 9 nt band 
in the acicular crystal. Similar to the B7 set, the level of incorporation is within the range of 4%-
14%. The pattern of poison incorporation was not the same as B7, even though B6 poisons had 
similar habit modifying effect as the B7 poisons. The only difference between B7 and B6 was the 
2-nucleotide difference in the Crick-Watson pair; this suggest that the Crick-Watson pair played a 
part in the stable incorporation of the poison oligomers.  
A 
Figure 5.9. Polyacrylamide gel analysis of B7 poison crystals. A. Lane 1, 1 non-poison crystal; Lane 2, ∆3’ 
alone; Lane 3, ∆5’ alone; Lane 4 and 5, 2 ∆5’ crystals; Lane 6 and 7, 2 ∆3’ crystals. B. Lane 1, 1 non-poison 
crystal; Lane 2, ∆5’ alone; Lane 3, ∆3’ alone; Lane 4, 1 tabular crystal; Lane 5, 1 hexagonal unipyramid 
crystal grown in the presence of ∆5’; Lane 6, 1 acicular crystal; Lane 7, 1 hexagonal unipyramid crystal 
grown in the presence of ∆3’; Lane 8, 1 hexagon column crystal grown in the presence of ∆5’ and ∆3’; Lane 




Figure 5.10. Polyacrylamide gel analysis of B6 poison crystals. Lane 1, non-poison crystal; Lane 2, B6 
∆5’ alone; Lane 3, B6 ∆3’ alone; Lane 4, tabular crystal; Lane 5, hexagonal unipyramid crystal grown in 
the presence of B6 ∆5’; Lane 6, acicular crystals; Lane 7, hexagonal unipyramid crystal grown in the 
presence of B6 ∆3’. Table of lane 6 shows percentage of gel band (Band), the percentage of B6 13 and 
B6 ∆3’ in original crystallization condition (Xtal Conditions) that the crystals came from and the ratio of 
the band to crystal conditions. Xtal = Crystal.  
Figure 5.11. Polyacrylamide gel analysis of non-poison hexagonal unipyramid crystals soaked in poison 
oligomers. Lane 1, B7 non-poison crystal; Lane 2, B7 ∆5’ alone; Lane 3, B7 ∆3’ alone; Lane 4 
hexagonal unipyramidal crystals in 300 µM ∆5’; Lane 5 hexagonal unipyramidal crystals in 1 mM ∆3’; 
Lane 6 hexagonal unipyramidal crystals in 1.25 µM ∆5’; Lane 7 hexagonal unipyramidal crystals in 
21.25 µM ∆3’; Lane 8 poison ∆5’ hexagonal unipyramidal crystal; and Lane 9 poison ∆3’ hexagonal 
unipyramidal crystal. 
13-mer Poison 13-mer Poison 13-mer Poison 13-mer Poison
Band (%) 95.45 4.55 88.06 11.94 89.90 10.10 86.71 13.29
Xtal Conditions (%) 98.16 1.84 98.16 1.84 57.14 42.86 57.14 42.86
Band/Xtal Conditions 0.97 2.47 0.90 6.49 1.57 0.24 1.52 0.31
13-mer Poison 13-mer Poison 13-mer Poison 13-mer Poison
Band (%) 78.19 21.81 95.06 4.94 90.50 9.50 91.09 8.91
Xtal Conditions (%) 97.71 2.29 99.77 0.23 70.67 29.33
Band/Xtal Conditions 0.80 9.54 0.90 6.49 1.28 0.32
Left Gel
Right Gel
Lane 4 Lane 5 Lane 6 Lane 7
Lane 4 Lane 5 Lane 6 Lane 8
Table 5.1. Analysis of Figure 5.9 gel bands. shows percentage of gel band (Band), the percentage of 
B7 13 and B7 ∆3’ or  B7 ∆5’ in original crystallization condition (Xtal Conditions) that the crystals 
came from and the ratio of the band to crystal conditions. Xtal = Crystal. 
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Next, we passively soaked the crystals in the poisons to ensure the poisons detected in the 
crystals were the result of active incorporation rather than simply residing in the solvent channels. 
To determine if the B7 poisons in (Figure 5.9) were actively incorporated into the lattice structure 
(Figure 5.11), hexagonal unipyramidal crystals were soaked in either high or low concentrations 
of ∆5’ or ∆3’. The high poison concentration used was equivalent to 2.5x the original 13-mer in 
the crystallization condition, and the low ∆5’ or ∆3’ concentrations used correlated to the poisons’ 
concentrations when they no longer exerted their habit modifying effect. Also, hexagonal 
unipyramidal crystals grown with poisons present were also collected to observe whether 
incorporation still occurred when there was no evident morphological changes. No low molecular 
weight bands were seen in any of the conditions, concluding that the poisons in Figure 5.9 were 
actively incorporated into the lattice structure and not a result of the poisons superficially adhering 
to the lattice. 
Chapter 5.2.4: Thermal stability of poison crystals  
 
We compared the thermal stability of the poison crystals to the non-poison crystals to 
evaluate whether their incorporation of the poison oligomers caused instability in the lattice 
structure. The B7 and B6 poison crystals, and non-poison crystals were incubated at 33˚C and their 
diameters were measured over time; for the acicular crystals, the width was measure perpendicular 
to the c-axis. The non-poison crystals were present the longest ( ≥ 5 hrs), followed by the tabular 
crystals (4 hrs)  and then the acicular crystals (3 hrs)  in both the B7 and B6 set (Figure 5.12). It is 
not clear though whether the rate of the complete dissolution was due to the incorporation of the 
poison oligomers alone. The morphology, as a result of the poison oligomers, could have 
influenced the rate of dissolution by changing the surface area to volume ratio (SA:V) of the 
crystals. The larger the SA:V value was, the more it would had been affected by the temperature.  
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All of the crystals tested had similar diameter (including the length of the acicular), but the SA:V 
of the crystals would vary depending on the morphology. The hexagonal pyramidal would have 
the smallest SA:V  and the poison crystals would have higher SA:V with the lost in either width 
or height in the presence of the poison oligomers (Figure 5.13). Based on the ratios of the crystals 
measured, the hexagonal pyramidal crystals had the smallest SA:V, followed by the acicular and 
tabular crystals. This showed a negative correlation between the SA:V of the crystals and the time 
it took for them to be completely disassembled. Therefore, the reason for the differences in the 
time it took for the crystals to be completely gone may not be necessarily due to the incorporation 
of the poison oligomers but due to the differences in SA:V between the different morphologies.  
Figure 5.12. Thermal stability poison of A. B7 and B. B6 poison tabular and acicular crystals at 33˚C. 
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Chapter 5.2.5: Layer-by-layer assembly with poison oligomers  
 
Detecting the poison oligomers in the crystals suggested that they likely did not exhibit 
their effects only at crystal nucleation or prenucleation, but also during crystal growth. To directly 
test if the poison strands influenced crystal growth, we performed post-crystallization layering by 
adding fresh oligonucleotides to pre-formed crystals serving as macroseeds (see Chapter 1). A 
small amount of 3' fluorescein modified 13-mer (Figure 5.1) was included to track the newly grown 
layer by confocal microscopy. Figure 5.14 shows a series of z-axis slices and 3D reconstructions 
of hexagonal unipyramid macroseeds in the presence and absence of poison strands. In the absence 
Figure 5.13. Theoretical crystal volumes (V), surface area (SA) and SA to Volume ratio of A. acicular 
crystals, B. hexagonal pyramid, C. of tabular crystals. Red lines are the same length. 
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of poison strands, a uniform fluorescent layer grew over the pyrimidal crystal surface (Figure 5.14 
A). In the presence of ∆5' the fluorescent layer showed preferential growth orthogonal to the six-
fold symmetry axis, leading to a significantly enlarged hexagonal base (Figure 5.14B). In the 
presence of ∆3' the crystals showed preferential growth down the six-fold symmetry axis, leading 
to the growth of a new columnar base region capped by the pyrimidal segment as observed in the 
3D reconstruction (Figure 5.14C) and in light microscope images (Figure 5.15A).  
 
 
Figure 5.14. Poison oligmers function as habit modifiers during crystal growth. 13-mer crystal macroseeds 
were grown in the absence of habit modifiers. The fluorescently-modified 13-mer tracks the layer grown on 
the macroseed. For each panel, three confocal z-stack images down the c cell axis are shown, followed by a 
3D reconstruction from all z-stack images, shown orthogonal to the c cell axis. A. Macroseed in the absence 
of poison displays uniform fluorescence accumulation. B. Shell growth in the presence of ∆5', leading to a 
new tabular layer that is significantly thicker along a/b than that in A. C. Layer growth in the presence of 
∆3' is columnar, showing apparent increase in the thickness of the shell layer toward the 'top' of the core 
pyramidal crystal. Clear changes in crystal morphologies based on layer growth are seen in the 3D 
reconstructions. Scale bars, 50 µm. 
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Remarkably, this axis-dependent growth was also observed when tabular or acicular 
crystals were used as macroseeds (Figure 5.16). Tabular crystals initially grown in the presence of 
∆5' showed uniform fluorescence layers in the absence of poison and began to grow as unipyramids 
(Figure 5.16A). Layer growth in the presence of ∆5' exacerbated the tabular morphology (Figure  
5.16B), while the presence of ∆3' led to growth down the c axis, resulting in columnar growth from 
the tabular base (Figure 5.16C & Figure 5.15B). Similarly, acicular crystals initially grown in the 
presence of ∆3' showed bidirectional layer growth parallel and perpendicular to the c axis without 
poison (Figure 5.15D), only growth orthogonal to the c axis with ∆5' (Figure 5.16 E), and primarily 
growth down the c axis in the presence of ∆3' (Figure 5.16F).  Using habit modifiers to control 
both the shape the crystal macroseed and the direction of crystal growth on that macroseed opens 
up the possibility for creating a highly diverse set of crystal morphologies. Significantly, it may be 
possible to achieve even greater levels of control by including both habit modifiers simultaneously, 
effectively tuning the growth characteristics.  
 
 
Figure 5.15. Light microscope images of crystals layered in the presence of ∆3’. A. Hexagon unipyramid 
used as macroseed. The macroseed is visible as the clear region at the center of the crystal. B. Tabular 
crystal used as macroseed. Scale bars: 70 µm. 
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Chapter 5.3: Conclusion 
Here, we have presented an approach to altering the macroscopic properties of a DNA 
crystal using designed oligonucleotide habit modifiers. The change in crystal habits to a tabular 
form in the presence of ∆5' and to an acicular form in the presence of ∆3' is fully consistent with 
the relative positions of the 5' and 3' nucleotides with respect to the duplex helical axes. The ability 
to control macroscopic crystal properties, including morphology provides an important step toward 
integrated control across scales: the construction of macroscopic objects of controllable shapes, 
and exploitable nanoscale features, such as the solvent channels in these crystals. The ability to 
control shape allows for tunable crystal properties. For example, apparent mass transport effects 
were observed when DNA crystals containing enzymes were incubated with substrate molecules26. 
By altering crystal shape, it may be possible to control crystal permeability and diffusion through 
the crystal by selectively adjusting crystal habits to generate solvent channels with different aspect 
ratios.  This demonstration provides a new branch of work in DNA crystal design through the 
Figure 5.16 Habit-modified crystals as macroseeds. Each panel contains a confocal image to show layering and 
a 3D reconstruction to show overall shape. A Tabular crystals grown without poison strands; B in the presence 
of ∆5'; C in the presence of ∆3'. D Acicular crystals grown without poi-son strands; E in the presence of ∆5'; F 
in the presence of ∆3'. Arrows indicate the direction of the c cell axis. Scale bars: 50 µm. 
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ability to alter both nanoscale and macroscale crystal properties. It is likely that other DNA crystal 
systems would be susceptible to habit modification using similar techniques. However, the relative 
orientation of DNA lattice contacts and crystal axes may require more involved design features 
than the simple truncations used here. 
 
Chapter 5.4: Materials and Methods 
 
Chapter: 5.4.1: Oligonucleotide synthesis and purification  
 
The non-modified oligonucleotides were ordered from IDT (Integrated DNA Technologies) 
and/or the fluorescein-labeled 13-mer (Figure 5.1) was synthesized on an Expedite 8090 DNA 
synthesizer (PerSeptive Biosystems) with reagents from Glen Research (Sterling, VA) using 
standard phosphoramidite synthesis and deprotection. Oligonucleotides were gel purified and 
electroeluted as previously described20 before dialysis against deionized water.  
Chapter 5.4.2: Crystallization 
 
Oligonucleotides were crystallized by sitting drop vapor diffusion. 2 µL of 200 µM 13 
nucleotide oligomer and 1 µL water were added to the sitting drop, followed by 1 µL of 
crystallization buffer (10% 2-methy-2,4-pentanediol, 120 mM magnesium formate, 50 mM 
lithium chloride). Drops were equilibrated against 300 µL of crystallization buffer. Crystal trays 
were incubated overnight at 22˚C.  
Crystals grown in the presence of poison oligomers were performed as described with the 
addition of 1 µL of the poison oligonucleotide (1 µM-2 mM) added in place of the water. 
Chapter 5.4.3: Macroseed layer growth 
 
Macroseed crystals were washed in 100 µL crystallization buffer prior to use. Macroseeds were 
transferred by nylon loop to a sitting drop containing 2 µL of crystallization buffer. 1 µL of 175 
µM 13-mer oligomer supplemented with 25 µM fluorescein-labeled 13-mer were mixed with 1 
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µL of poison oligonucleotides (1 µM-1 mM)  in the drop. The sitting drop was equilibrated 
against 300 µL of crystallization buffer and incubated overnight at 22˚C.   
Chapter 5.4.4: Visualization and measurements   
 
Light microscope crystal images were taken of the crystals in the sitting drop on a stereo 
microscope with an attached CCD camera. The fluorescein-incorporated layered crystals were 
imaged with a Leica SP5X confocal microscope. Prior to visualization, crystals were washed in 
100 µL crystallization buffer and then transferred to a 200 µL crystallization buffer on a 35 mm 
glass bottom culture dish with 14 mm microwell. The fluorescein layer was visualized by 
excitation at 480 nm. Z-stack images were collected every 1 µm. Measurements and 3D 
reconstructions were performed in ImageJ100. 
Chapter 5.4.5: Crystal radiolabeling 
 
Crystals were washed in 100 µL crystallization buffer for 5', dipped briefly in 100 µL water 
before being transferred to 7.6 µL water to allow the crystals to dissolve. 1 µL 10X T4PNK 
Reaction Buffer, 0.4 µL T4 polynucleotide kinase (New England Biolabs),and 1 µL of 50 pmol 
[γ-32P] ATP (PerkinElmer) were added and incubated at 37˚C for 30'. Reactions were terminated 
at 65˚C for 20'. Samples were mixed with denaturing loading buffer and loaded onto a 20% 
denaturing polyacrylamide gel (19:1). The gel was exposed onto a phosphor screen and the 







Chapter 6: Conclusion and Future Prospects   
 
My Ph.D work has contributed methods and tools to facilitate and improve the utilization 
of 3D DNA crystals. One of the milestones was to increase the stability of the crystals by treating 
the 13-mer DNA crystals with a chemical cross-linker and/or the deposition of PDA. The 
chemical cross-linker, NOR, stabilized the crystal lattice directly through the formation of an 
interstrand crosslink using the free terminal nucleotides. The deposition of PDA onto/into the 
crystals was an alternative method discovered to stabilize the crystals. Although, it is unclear 
exactly how PDA stabilizes the crystal lattice, it is believed that the PDA can potentially act as a 
net for magnesium, therefore trapping the positively charged divalent cation essential for DNA 
nanostructure stability. Both treatments have successfully improved the thermal stability, 
stability at low magnesium concentration, and/or stability in simulated biological conditions. The 
development of these methods to increase the overall durability of 3D DNA crystals will 
facilitate the transition of DNA crystals for utilization for certain applications. For example, the 
increased durability could potentially allow the crystals to be repurposed as a drug delivery 
device where they would be exposed to an environment of low magnesium concentration, 
relatively higher temperatures and attacks from phosphodiesterase.  
My work with stabilizing the DNA crystals has helped other projects in our lab and has 
the potential to be applied to other DNA nanostructures to improve their overall stability. In our 
lab, the use of NOR has decreased the degradation of the crystals during multiple manipulation 
with guest molecules that are to be incorporated into the solvent channels; specifically the 
incorporation of gold nanoparticles into a version of the 13-mer crystals with expanded solvent 
channels. NOR treatment has the potential to increase stability of other DNA nanostructure 
through the introduction of free terminal guanine nucleotides into the sequence. The concept of 
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using a chemical crosslinker can be further explored by testing other chemical crosslinkers, such 
as crotoaldehyde114, which may improve durability further or stabilize the structure without the 
requirement of free terminal nucleotides. Furthermore, PDA provides an alternative, more 
passive method for stabilizing DNA nanostructures where no changes are made to the original 
sequence and only requires a simple single-step deposition method to coat the DNA 
nanostructure.  
Additionally, my work in predictably modifying DNA crystal morphology is the first 
example of its kind in the nanotechnology field. I accomplished this by designing habit modifiers 
based on the structural information given by the X-ray diffraction of the 3D DNA crystal. The 
habit modifiers acted as poisons on the crystallization process and inhibited the growth in certain 
directions resulting in acicular and tabular versions of the original morphology. Furthermore, the 
habit modifiers can also be combined, allowing us to further modulate between the acicular and 
tabular morphologies. In addition, the habit modifiers’ action are not limited at nucleation and 
can act upon the macroseed during layer-by-layer assembly30. Being able to change the 
morphology of crystals can potentially improve the permeability and diffusion of the substrate 
into or out of the solvent channels, and uptake by cells24. Therefore, this has the potential to 
improve the DNA crystals for nanotechnological applications, such as for drug delivery.   
The ability to increase the durability and change the morphology of the 3D DNA crystals 
widens the application possible for this class of DNA nanostructure. Some of the potential 
applications made possible are the usage of the 3D DNA crystal as potential drug delivery device 
and the alignment of nanoparticles within the solvent channels. Our lab has taken the first step 
towards exploring the crosslinked 3D crystals as a drug delivery device by testing the 
incorporation of DOX within the solvent channels. I used confocal microscopy to confirm that 
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DOX was extensively incorporated within the crystal lattice. Interestingly, the crosslinked 
crystals showed added benefits of increasing the load capacity and retention of the DOX inside 
the crystal compared to the non-crosslinked crystals. This is believed to be possible due to the 
transition of the crystal lattice into a gel matrix upon addition of DOX, although the mechanism 
behind how this was occurred in the crosslinked is unclear.   
The next step should be to focus on controlling the growth of the crystals, thus the size, 
which will further improve the feasibility of 3D DNA crystals for nanotechnological 
applications. The size of the 3D DNA crystals needs to be in the nanosize range in order for it to 
be probable as a vesicles for drug delivery, but the 3D DNA crystals normally range in size 
between 50 µm - 100 µm. Nanoparticles for drug delivery needs to be large enough in order to 
avoid rapid elimination by the kidneys115 and small enough to avoid accumulation in the spleen 
and liver116. The effective range for a drug delivery device would be between 30 and 200 nm. 
Potential methods for controlling the size would be to either focus on the crystallization 
condition or mechanically breaking the microsize crystals into nanosize crystals. Additionally, a 
technique would be needed to separate the crystals by size in order to get the ideal range for drug 
delivery. Rate-zonal centrifugation has proven to be effective for purification of DNA origami117 
and may be possibly optimized for DNA crystals.   
Once nanosized crystals are obtained, the DOX crystals can be tested for efficacy through 
tissue cultures or animal models. The efficacy of the DOX-incorporated can be compared to 
DOX alone, with other DNA nanostructures such as DNA origami or DNA icosahedra which 
have been tested in tissue cultures and mice24,25. Additionally, we can vary the shape and see 
how that affects the efficacy and distribution since previous studies with DNA nanostructures 
had shown that shape can have an effect24. Furthermore, the layer-by-layer assembly allows 
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customization of the outer layer with guest molecules30 that could potentially increase efficacy 
such as attaching antibodies targeted towards specific surface proteins of the intended cells. 
Overall, my Ph.D work with DNA crystals has the potential to advance its usage for 
nanotechnological applications by overcoming limitations inherent to these structures. The 
simple methods of using NOR or PDA deposition to increase overall durability has improved the 
integrity of the 3D DNA crystals in our lab during their utilization, such as the incorporation of 
DOX. Likewise, the principles of using a simple chemical crosslinker or PDA deposition method 
to stabilize structures may be broadly applicable to other types of DNA nanostructures as well. 
Additionally, the design of habit modifiers that can predictably control the shape for the first 
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